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1 Introduction
1.1 Meningococcal disease
Neisseria meningitidis, as we know the bacterium today, is thought to be a fairly new 
microbial pathogen which developed only a couple of hundred years ago (1). The first known 
descriptions of meningococcal disease are from outbreaks in Switzerland in 1805 and 
Massachusetts in 1806 (2-4). The first description from Africa, where the largest epidemics 
of this disease still appear regularly, is from Nigeria in 1905 (5). Given the characteristic 
appearance of meningococcal disease with hemorrhagic rash, meningitis and rapid 
progression to death, sometimes in epidemic outbreaks, it is suggested that the lack of 
description in previous medical literature, being extensive for its period, actually means that 
the disease did not occur (1). It is likely that harmless Neisserial commensals, adapted to 
inhabit the nasopharynx in humans, became transformed into virulent bacteria due to uptake 
of DNA from other surrounding bacteria coding for virulence factors such as the ability to 
make a capsule (6). Unlike other Gram-negative bacteria, N. meningitidis is naturally
competent for genetic transformation throughout its entire life cycle (7).
N. meningitidis was first observed in the cerebrospinal fluid during an epidemic of 
cerebrospinal fever in Italy by Marchiafava and Celli, published in 1884 (8). They described 
the visual resemblance to N. gonorrhoae in some of the patients due to massive intracellular 
accumulation of bacteria. N. meningitidis was first isolated from the cerebrospinal fluid by 
Anton Weichselbaum, a pathologist in Vienna, in March 1885, published in 1887.
Weichselbaum named it Diplococcus intracellularis meningitidis (9).
The asymptomatic carrier state of N. meningitidis in the throat of humans was first described 
in 1896 (10). Meningococci are transmitted through close contact by droplets and colonizes 
the nasopharynx in about 10% of the overall healthy population with peak carriage rate 
reaching about 25% among late adolescents estimated by throat swabs (11,12), which in fact 
may underestimate the carriage rates (13). In closed communities, including military 
barracks, the carriage rate may reach 90-100% (1,12). Carriage is an immunizing event 
leading to protective immunity against the microbe (14).
Only occasionally does acquisition of N. meningitidis lead to meningococcal disease, usually 
within a few days after transmission (15). A number of host factors influence the risk of 
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acquiring invasive disease, of which lack of protective antibodies is the most important (1).
Other factors include complement deficiencies, 	
-		-RIIa, 
 -		  -RIIIb, CD16), other genetic polymorphisms affecting the 
immune response, exposure to cigarette smoke, preceding airway infections or climatic 
changes, i.e. dust and sand that damage the nasopharynx epithelium during the dry season in 
sub-Saharan Africa, influence the risk of acquiring invasive disease (1,15,16). In addition, 
the virulence of the carried strain is of great importance. Most of the meningococci carried in 
the nasopharynx are devoid of a capsule and have limited pathogenic potential (1).
Meningococcal virulence is related to both capsule expression, expression of other surface 
structures like pili and the major outer membrane protein porin PorA, secretion of IgA 
proteases, sialylation of LPS and the underlying genotype (14-17).
There are so far 13 serogroups of N. meningitidis defined based on different capsular 
polysaccharide structures, but only six serogroups (A, B, C, W-135, X, and Y) cause most 
life-threatening disease (12,14,18). Strains of serogroups B and C cause the majority of 
infections in industrialized countries where pathogenic strains tend to cause single cases or 
small clusters of disease. Strains of serogroup A and, to a lesser extent, serogroup C 
dominate in third-world countries where they cause large outbreaks, particularly in the 
meningitis belt of sub-Saharan Africa (15,18,19). However, during the last 10-15 years 
approximately 1/3 of all cases in USA were caused by strains expressing serogroup Y which 
also has occurred with increased frequency in Sweden, Israel and South Africa (16,20,21).
The last decade serogroup W-135 has caused large outbreaks in Saudi Arabia and Africa, and 
smaller outbreaks of serogroup X has also been seen in Africa (18).
Although N. meningitidis may cause localized infections like pneumonia (particularly 
serogroup Y) or sinusitis by spreading from the nasopharynx to adjacent epithelial structures, 
meningococcal disease is normally initiated by meningococci breaching the nasopharyngeal 
mucosa in susceptible people with subsequent development of bacteremia (14). The growth 
velocity in the circulation is the major determinant of the clinical presentation and outcome 
(15). The most common clinical presentation of meningococcal disease is distinct meningitis 
with headache, stiff neck, fever and sometimes petecchiae. Such patients have low numbers 
of bacteria (<103 meningococci/mL) and low amounts of LPS (<0.5 EU/mL) in their 
circulation, but high bacterial numbers and high amounts of LPS in the cerebrospinal fluid 
(22-25). They are normally admitted to hospital within 1-2 days after onset of the first 
symptoms and have low mortality if given antibiotics within due time (14). A minority 
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rapidly develops fulminant septic shock without signs of meningitis. These patients have 
extremely rapid proliferation of meningococci in their blood, typically reaching 105 – 108
bacteria/mL and LPS concentrations in plasma >10 EU/mL within 12 hours after the first 
onset of symptoms. The mortality is high, varying from 20 to 80% in different studies, 
despite rapid admittance to hospital within few hours after onset of the disease and adequate 
treatment (19,22-25). No other invasive bacterial disease in humans progress more frequent 
to fulminant septic shock with multiorgan failure. Occasionally, patients develop distinct 
meningitis and persistent shock  simultaneously (19). Up to 30% of patients admitted to 
hospital neither have distinct meningitis or fulminant septicemia, but normally present with 
fever and a rash. They have low bacterial load and level of LPS in the circulation and the 
subarachnoid space, but they may develop meningitis or shock if untreated (14). Transient 
meningococcemia also occurs, presenting with fever and an uncharacteristic “viral” rash. 
Meningococci are usually detected as an unexpected finding in blood culture, and the disease 
may be self limiting. Chronic meningococcemia appears as a rare condition that can last from 
week to months with intermittent fever, arthralgia and a non-specific maculopapular rash 
(14). Rarely, meningococcal infections can also result in pericardial infection, purulent or 
immune complex arthritis, cutaneous vasculitis (particularly in sub-Saharan Africa), 
conjunctivitis or panophtalmitis, and infections of the urogenital tract (14,15).
1.2 Meningococcal sepsis: A brief overview of inflammatory and 
pathophysiological mechanisms
The circulatory collapse associated with the fulminant course of meningococcal sepsis occurs
due to capillary leakage, inappropriate vascular tone, intravascular microthrombi, and 
myocardial dysfunction (14,19). These changes are caused by an overwhelming 
inflammatory response in the host. 
High cytokine concentrations correlate with the severity of shock. The first cytokine to be 
described as an important factor in the development of sepsis was TNF- 	 
Beutler et al. in 1985 to be a key factor in the development of septic shock in a murine model 
of endotoxemia (26). In 1987 Waage et al. reported for the first time that TNF-
concentrations in serum correlated with mortality in meningococcal disease (27). Similar 
patterns were subsequently reported for other pro-inflammatory cytokines, of which IL- 
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and IL-6 are regarded as the most important, and also for chemokines like IL-8, as well as for 
anti-inflammatory cytokines, of which IL-10 is regarded as the most important (19,28-31).
A key function of the pro-inflammatory cytokines is to enhance leukocyte migration out of 
blood vessels and promote diffusion of plasma proteins like antibodies and complement to a 
potential site of infection (32,33). These effects are mediated by activation of endothelial 
cells and circulating leukocytes with up-regulation of adhesion molecules like E-selectin, 
P-selectin, ICAM-1 and VCAM-1, increasing the endothelial permeability, and slowing the 
blood flow by vasodilatation which allows tethering of neutrophils to the vessel wall (32,33).
Neutrophils being adherent to endothelial cells further increase the permeability by secreting 
a number of inflammatory molecules including a variety of proteases acting locally (33,34).
Moreover, local ischemia occurs due to small vessel obstruction caused by an increased pro-
coagulant state and further increases the capillary leakage (32,35). Increased systemic 
procoagulant activity results primarily from up-regulation of tissue factor on monocytes and 
monocyte derived microparticles, activating coagulation by the extrinsic, i.e. factor VIIa 
dependent pathway (36-38). The adhesion of activated platelets expressing P-selectin to 
activated endothelial cells also contributes to the forming of microthrombi in the tissues (38)
. Concurrently, reduced antithrombotic capacity appears due to reduced levels and function 
of antithrombin and particularly protein C as well as down-regulation of the fibrinolytic 
system, caused by high levels of functionally active PAI-1 released into the circulation 
(14,38,39). Disseminated intravascular coagulation (DIC) ultimately develops. Thrombosis 
occurs particularly in the vessels of the skin, adrenals, kidneys, muscles, choroid plexus, 
peripheral extremities, and to some extent in the lungs (6).
The inflammatory plasma contact systems involving the complement system and the 
kallikrein-kinin system forming bradykinin are also activated and such activation may have 
additional inflammatory effects including contributing to decreased vascular tone and 
increased permeability (14,32,40-42). Activation of complement releases potent pro-
inflammatory molecules like C5a which has been suggested to have disadvantageous effects 
in sepsis, given the massive release, by acting through its receptor C5aR being localized on 
myeloid and non-myeloid cells (10,43-45). Systemic complement activation in patients with 
meningococcal sepsis is associated with a poor outcome (40,43). Complement also 
constitutes an essential part of the defense system against meningococci (46). The two main 
anti-bacterial activities by complement are opsonization for phagocytosis by deposition of 
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C3b and C4b fragments on the membrane and lytic insertion of membrane attack complex 
(MAC, C5b-9). Of these, insertion of C5b-9 is recognized as the most important mechanism, 
whereby the role of opsonization has been less clear (47-49).
In general, the various inflammatory responses described in sepsis are beneficial to fight a 
localized infection. For example the migration of leukocytes and the accumulation of plasma 
defense proteins like antibodies and complement to a site of localized infection is obviously 
essential to clear the pathogens. Likewise, the formation of localized blood clots can be 
beneficial in preventing the pathogens to spread. However, when these responses progress to 
affect the whole organism, inducing the systemic inflammatory response syndrome (SIRS),
they easily come out of control with devastating effects. 
It is becoming increasingly evident that SIRS is a result of multiple inflammatory factors 
acting in concert. Despite promising results from animal models of sepsis (50,51), so far no 
convincing therapeutic effect has been obtained by blocking individual cytokines, although 
there are indications that some effect may be obtained by treating selected subgroups of 
patients with  inhibition of TNF- (52-55). Also, clinical trials blocking other mediators in 
sepsis including PAF, bradykinin, prostaglandins and antithrombotic therapy by using 
antithrombin or a tissue factor pathway inhibitor has shown no benefit (56-61). However, in 
2001 antithrombotic therapy by the use of activated protein C was reported to be beneficial 
in a clinical trial (62). Controversy still exists with respect to the validity of the results, but 
the agent has been accepted for treatment of adults with severe sepsis. Thus, with few 
exceptions the results of targeting specific mediators in sepsis are disappointing. 
Consequently, focusing on a broad range of inflammatory responses may be a more tempting 
approach, and a multimodal therapy targeting different pathophysiologic pathways with 
possible additive or synergistic effects may be more helpful than one “magic bullet”
(52,63,64).
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1.3 The role of LPS and other components of N. meningitidis in septic 
inflammation
LPS is a major constituent of the outer membrane of N. meningitidis (Figure 1). It has long 
been regarded to be the principal molecule inducing inflammation by Gram-negative bacteria 
(65). Richard Pfeiffer, a German bacteriologist, was in 1892 the first to describe the 
inflammatory effect of endotoxin (46). He detected that Vibrio cholerae contained two 
different toxic principles; one that caused diarrhea and could be inactivated by heating, i.e. 
the cholera exotoxin. The second principle was resistant to heating and caused a toxic-shock 
reaction in guinea pigs. It was thought to reside inside the bacterium and thus named 
endotoxin. Netter and Debré stated in 1911 that endotoxin represented the main toxic 
principle of meningococci (66).
Fig. 1: The membrane structures of N. meningitidis (Stephens D.S., B. Greenwood, and P. 
Brandtzæg. 2007. Lancet. 369: 2196-2210, with permission from Elsevier)
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Purification and characterization of endotoxin from lysates of Gram-negative bacteria 
required substantial efforts from several researchers and the term LPS was applied by Otto 
Lüderitz and Otto Westphal due to the presence of polysaccharide and lipid components (67).
N. meningitidis LPS consists of lipid A, a core structure containing two 2-keto-3-deoxy-
octulosonic acid (KDO) and two heptoses (L-glycero-D-manno-heptopyranoside) substituted 
with variable short polysaccharide    side chains (68,69) (Figure 2). The complete 
biosynthesis pathway of N. meningitidis LPS has been described (69). While the biological 
activity of enteric LPS resides in the lipid A structure alone, maximum biological activity of 
N. meningitidis LPS requires the two KDO components linked to lipid A (70).  The numbers 
of acyl chains attached to lipid A and their pattern of attachment are important determinants 
of the biological activity of LPS (69,71).The predominant and biologically most active form 
of N. meningitidis LPS is symmetrically hexa-acylated (71,72). However, invasive strains of 
N. meningitidis being penta-acetylated due to mutations of lpxL1 or lpxL2 genes required for 
addition of secondary acyl chains have also been reported to occur being associated with less 
systemic inflammation and reduced activation of the coagulant system (73).
Fig. 2: The structure of N. meningitidis lipopolysaccharide (LPS) (Diaz Romero J., and 
I.M. Outschoorn. 1994. Clin. Microbiol. Rev. 7: 559-575, with permission from the 
American Society of Microbiology)
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The lipid A structure of E. coli is, in contrast, asymmetrically hexa-acylated with different 
length of the acyl groups (72). Also in contrast to enteric LPS, N. meningitidis LPS has short 
polysaccharide chains and lack repeating O antigen units and, thus, is sometimes referred to 
as lipo-oligosaccharide (LOS) (68). The LOS structure is common among other mucosal
pathogens, including Bordetella pertussis, Campylobacter jejuni and Haemophilus species
(70). Differences in the oligosaccharide structure of LPS forms the basis of immunotyping 
N. meningitidis (L1-L12) (17). Most strains express more than one immunotype-specific 
epitope on their LPS (17).
The levels of LPS in blood and cerebrospinal fluid of patients infected with N. meningitidis 
are closely associated with the clinical presentation and outcome (6,68,74,75). So far, this is 
the only Gram-negative infection where a dose response relationship has been thoroughly 
documented by measurement of LPS in different human body fluids (6,68). In vitro 
examination of meningococcal shock plasma in a monocyte target assay support the role of 
LPS as a major activator of monocytes (75), and studies using cell lines and whole blood 
models challenged with wild type meningococci and an LPS-deficient mutant of 
N. meningitidis document the potency of LPS as an activator of the innate immune responses 
(76-78).
The first protein specifically binding LPS was described as LPS-binding protein (LBP) in 
1986 (79). Concomitantly, in 1990 CD14 was also shown to be essential for LPS sensing 
(80). The discovery of the transmembrane signaling pattern recognition receptors TLRs in 
the late 1990’s, as proposed by Charles Janeway Jr in 1989 (81,82), implied a new era in our 
understanding of the sensing of microbial structures like LPS by the innate immunity. The 
first TLR described to be activated by microbial structures was TLR2, in 1998 reported to be 
the receptor of LPS (83,84). A couple of years later it was shown that these results were due 
to contamination of the LPS preparations with lipoproteins (85). At the same time mutations 
in the TLR4 gene of mice were reported to be responsible for defective LPS signaling 
(86,87). Short time later MD-2 being in complex with TLR4 was shown to be a prerequisite 
for LPS-mediated signaling (88). Activation of TLR4 induces the MyD88 dependent 
intracellular signaling pathway being common for all TLRs except TLR3, ultimately 
activating the transcriptional factor NF-!"	
#			
a range of inflammatory molecules (89). Additionally, TLR4 also activates the TRIF 
intracellular pathway which is used only by TLR3 and TLR4, leading to production of         
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-interferon in addition to activation of late phase NF- !" (89). LPS from different Gram-
negative bacteria activate the MyD88 dependent and the TRIF intracellular pathways to 
various extents. N. meningitidis LPS is a potent inducer of both pathways in monocytes 
(90,91). In contrast, Salmonella LPS predominantly activates the TRIF intracellular pathway 
while E. coli (55:B5) and V. cholerae LPS predominantly activate the MyD88 dependent 
pathway (90)$%& 
'( 	&	
))
 
-interferon 
and subsequently activation of the JAK/STAT signaling pathway seems to be responsible for 
activation of a large group consisting of more than 2000 genes induced by N. meningitidis in 
monocytes being particular LPS-sensitive according to micro array studies (91).
Although LPS has been shown to be the most potent inflammatory molecule of 
N. meningitidis, non-LPS bacterial compounds (Figure 1) have also been shown to have the 
capacity to induce pro-inflammatory cytokines, and complement activation by meningococci
occurs independently of LPS (76-78,92,93). Also the cell adhesion molecule E-selectin has 
been shown to be up-regulated independently of LPS at high bacterial concentrations, while 
the adhesion molecules ICAM and VCAM were shown to be up-regulated strictly dependent 
on LPS (94). TLR2, primarily associated with ligands from Gram-positive bacteria (95,96),
was in 2000 the first receptor described to mediate inflammatory signaling also by 
meningococcal structures other than LPS (78). Of these, the interaction between outer 
membrane protein porin B and TLR2 has been described in most detail (97-99).  Also 
peptidoglycan, constituting a thin layer between the outer membrane and the cytosolic 
membrane of Gram-negative bacteria and shed during bacterial growth, has been 
demonstrated to be a ligand of TLR2, as well as intracellular NOD2 receptors 
(84,95,100,101). The effects of such activation seem to be additive to TLR4 mediated 
activation (97). Unmetylated CpG sequences in DNA molecules, being more abundant in 
bacteria than in vertebrates, activate innate immunity by being a TLR9 ligand (102,103).
Also, native IgA1 protease, a putative virulence factor of N. meningitidis, has been shown to 
be a potent stimulus for the secretion of pro-inflammatory cytokines by monocytes, although 
the mechanism has not been fully established (104). However, in general it appears from 
experiments in various in vitro systems that the potency of non-LPS structures of 
meningococci to induce inflammation is much weaker than LPS but until now this has been
scarcely tested in vivo (76,78).
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1.4 The viable N. meningitidis devoid of LPS as a valuable research tool 
An LPS-free mutant of N. meningitidis, described in 1998, was constructed by the research 
group of Peter van der Ley by insertional inactivation of  the enzyme LpxA which is 
responsible for the first committed step in the lipid A biosynthesis (105). In fact, the wild-
type parent reference strain 44/76 which was transformed to the LPS deficient mutant 
44/76lpxA- was originally isolated from a woman admitted to Ullevål Hospital (presently 
Oslo University Hospital) in the late 1970ies (106). N. meningitidis is the only known Gram-
negative bacterium being viable without LPS in the membrane. This mutant bacterium has 
paved the way for more detailed studies of the specific role of LPS versus other bacterial 
compounds in the inflammatory response, and has been essential for several of the studies 
referred to above concerning LPS-specificity of the inflammatory response elicited by
N. meningitidis.
1.5 Experimental meningococcal sepsis: Animal models
Humans are the only natural hosts for N. meningitidis. This is partly due to the specificity of 
surface proteins of meningococci in their interaction with surface proteins of human cells, 
including the interaction of pili with human CD46 and Opa and Opc with human CEACAM1
(CD66) (107). Such interactions are crucial for the colonization of nasopharyngeal mucosa 
and invasion of the host. Moreover, neisserial iron uptake systems bind only human iron 
transport proteins, such as transferrin and lactoferrin (108).  Thus, meningococci can only 
proliferate in human blood. Still, animal models for meningococcal disease have a long 
history. Early attempts used monkeys, rabbits and guinea pigs but the first useful model was 
developed in the 1930s where mice were infected by the intraperitoneal route. 
Coadministration of mucin, which has later been shown to serve as an exogenous source of 
iron available for the meningococci, was necessary for progression to meningococcal disease 
(109). Variants of the mouse model have in the passing years found some use in 
meningococcal research. More recently a transgenic mouse has been developed expressing 
human CD46. These mice can develop meningococcal sepsis and meningitis by nasal 
administration of meningococci (109). In 1999 Hazelzet et al. published a live porcine model 
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and documented the potent biological effects of LPS-containing outer membrane vesicles 
when infused as a bolus dose (110).
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2 Aims of the present studies
I. To examine the involvement of TLRs and complement in inflammation induced 
by escalating doses of N. meningitidis stimulating whole blood and transfected 
cell lines
II. To examine the effects of congenital deficiencies of complement factors C2 and 
C5 on phagocytosis and killing of N. meningitidis in whole blood and serum 
models
III. To examine the effect of opsonization by complement on the binding of Gram-
negative bacteria to erythrocytes by complement receptor CR1, and the effect of 
such binding and the formation of C5a on phagocytosis in whole blood
IV. To develop a new large animal model challenged with exponentially increasing 
doses of heat-killed N. meningitidis simulating fulminant meningococcal 
septicemia in man
V. To study the effects of LPS in heat-killed wild type N. meningitidis (44/76) versus 
other inflammation inducing molecules of meningococci using the isogenic knock 
out mutant 44/76lpxA- completely lacking LPS in the new porcine shock model
The general aim of this thesis was to investigate key elements in the interaction between the 
meningococcus and the immune system. Meningococcal sepsis represents a prototypical 
example of how the immune response elicited by a pathogen is crucial to protect against 
disease on the one hand, but can be detrimental for the host on the other hand (111). A 
profound understanding of either of these dual aspects is of fundamental importance to 
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understand the nature of meningococcal disease. Also, although meningococcal sepsis 
distinguish itself from most other septic conditions by the exceptionally rapid growth of 
bacteria, this disease can be used as a model to gain novel insight into common principles of 
how pathogens trigger inflammation, and the impact of the inflammatory responses on the 
host as well as the pathogen. The studies in this thesis were performed in vitro to investigate 
the inflammatory response and defense mechanisms against N. meningitidis at a molecular 
level, while the in vivo studies were performed to investigate pathophysiological mechanisms 
and the inflammatory response of the whole organism in meningococcal disease.
Ad study I
In this paper we first focused on the inflammatory response to N. meningitidis as regards
activation of the innate immune system. TLR-mediated cell activation and activation of 
complement represent two main branches of innate immunity (111). Inflammation induced 
by activation of these two systems after exposure to meningococci has only been investigated 
separately in previous studies. However, there is substantial cross-talk between the two 
branches (111). Thus, we were interested in the relative role they play and how they interact. 
We aimed to simulate the different stages of meningococcal sepsis in vitro, with the numbers 
of meningococci present ranging from the low numbers typically found in low-grade
meningococcemia with subsequent development of meningitis to the high numbers typically 
found in fulminant sepsis (23-25). The studies were therefore performed with different 
numbers of meningococci added, paralleling the numbers found in patients with various 
clinical manifestations of meningococcal disease. We also intended to compare the relative 
role of the two branches in the presence and absence of LPS to gain more information about 
how this important inflammatory molecule specifically influences the innate immune 
responses.
Ad study II
We then focused on the role of complement in the defense against systemic meningococcal 
disease taking advantage of whole blood and serum from human beings genetically 
completely deficient of C2 and C5, respectively. The C5 deficient donor and its control 
individual were also deficient of MBL. The donors differed in their respective titer of anti-
meningococcal antibodies, and thus we also focused on the specific role of antibodies. 
Deficiencies of the complement system in the alternative pathway, C3 and the terminal 
28
pathway are predominantly associated with increased susceptibility to meningococcal disease 
(112,113). Acquisition of serum bactericidal antibodies correlates with protection (114,115).
Opsonophagocytosis of meningococci opsonized with C3 and C4 split products may also be 
important in the defense against meningococcal disease, but the relative role of these two 
complement mediated defense mechanisms in the presence of various amounts of anti-
meningococcal antibodies is not fully clarified (47-49). First, we studied to what extent 
meningococci can survive and proliferate in whole blood from the respective complement 
deficient donors and controls. Subsequently, we studied how serum bactericidal activity and 
opsonophagocytosis each was influenced by the respective defects of complement in the 
presence of high and low titers of anti-meningococcal antibodies. 
Ad study III
The immune adherence phenomenon was originally described in 1953 by Nelson as binding 
of Gram-positive bacteria opsonized with C3 and C4 split products to CR1 on erythrocytes
(116). Other particles like complement opsonized virus and immune complexes can also 
adhere to erythrocytes by binding to CR1 (117), and such binding can probably be an 
important mechanism for clearing of hazardous agents from the circulation by shuttling them 
to macrophages in the liver and spleen for safe deposition (116-118). Binding of Gram-
negative bacteria to erythrocyte CR1 has not been demonstrated before. Also, the influence 
of such binding on phagocytosis by circulating leukocytes has not been investigated 
previously. Thus, we performed experiments to demonstrate binding of Eschericia coli and 
N. meningitidis to human erythrocyte CR1 and how binding to CR1 affects the phagocytosis 
of these bacteria by granulocytes and monocytes.
Ad study IV
We established a large animal model of meningococcal sepsis to elucidate inflammatory 
responses to N. meningitidis and how these responses result in the clinical state of 
meningococcal sepsis with development of circulatory failure and subsequently organ 
dysfunction. Such a model could also be useful for further more detailed studies of specific 
inflammatory and pathophysiologic aspects of meningococcal sepsis, as well as to investigate 
new potential therapeutic principles. For this purpose a porcine model simulating the fast 
growth of bacteria in the circulation was established. 
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Ad study V
We investigated the specific role of LPS and non-LPS structures of N. meningitidis in 
triggering inflammation and associated pathophysiological changes in vivo. The effect of 
administrating wild-type and the LPS-deficient mutant N. meningitidis in the previously 
established porcine model of meningococcal sepsis was compared. A previous study of 
mortality in mice demonstrated that high numbers of the LPS-deficient mutant 
meningococci, i.e. about 2 log10 higher numbers than the wild-type strain, were able to kill 
mice (76).  Apart from this study, not other more detailed studies have previously been 
performed with the LPS-deficient mutant N. meningitidis in vivo.
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3 Materials and Methods 
3.1 Bacteria and LPS
In all papers in this thesis the international reference strain N. meningitidis 44/76 (also 
denoted H44/76 and herein called NmLPS+) isolated from a patient with meningococcal 
sepsis  was used (106). The bacterium is phenotypically characterized as 
B:15:P1.7,16:L3,7,9. This characterization is based on differences in the polysaccharide 
capsule (serogroup B), the outer membrane protein por B (serosubtype 15), the outer 
membrane protein por A (serosubtype P1.7,16) and the oligosaccharide structure of LPS 
(immunotype L3,7,9). The strain belongs to the MLST 32/ET-5 clone, based on genotypical 
classification.
In paper I N. meningitidis 151/85 (strain collection, National Institute of Public Health, Oslo, 
Norway, called NmC in this thesis) was also used. This bacterium is characterized as 
C:2a:P1.2:L3,9. It is a representative strain of the MLST 11/ET-37 clone and was isolated 
from a six month old boy who died from fulminant meningococcal septicaemia in 1985. 
Pathogenic meningococci belonging to the MLST 32/ET-5 and MLST 11/ET-37 clones have 
been isolated all over the world.
The mutant N. meningitidis 44/76lpxA- (also denoted H44/76lpxA- and herein called  
NmLPS-) was used in paper I, III and V (105). The expression level of the integral outer 
membrane proteins by the LPS-deficient mutant is slightly higher than that of the wild-type 
strain. The outer membrane phospholipid composition is altered, with a switch to mostly 
short-chain, saturated fatty acids (119).
The meningococci were grown by the National Institute of Public Health (Oslo, Norway) on
Colombia-agar and resuspended in sterile PBS after overnight growth. The bacteria used in 
paper I, III, IV and V were heat inactivated at 56°C for 30 minutes and then frozen at -70°C 
until used. The membrane structures of heat killed N. meningitidis are as biological active as 
those of viable meningococci of the same strain (102,120). However, such treatment of the 
bacteria reduces TLR9 signaling by CpG DNA (102).  In paper II viable meningococci were 
used. 
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In paper III experiments were also performed with E. coli strain LE392 from ATCC
(Manassas, VA; ATCC Number 33572). E. coli were grown by the research laboratory at 
Nordlandssykehuset, Bodø. The bacteria were first grown overnight on a Lactose dish, and 
then transferred to LB-medium (Becton Dickinson, Franklin Lakes, NJ) and grown 
overnight. They were then resuspended and washed once with PBS, heat inactivated for 1 
hour at 60°C and stored at -80°C. After thawing the bacteria were washed six times with PBS 
to remove extracellular LPS. Bacteria intended for Alexa-staining were removed and the rest 
were washed additional three times. Bacteria were counted in Truecount tubes (Becton-
Dickinson) using flow cytometry after staining with SytoBC (Invitrogen Molecular Probes
Carlsbad, CA).
In the phagocytosis assay in paper III, Alexa 488 labeled E. coli and N. meningitidis were
used. NaHCO3 and heat inactivated bacteria were added together with Alexa FLUOR® 488 
carboxylic acid and succinimidyl ester (10 mg/mL) in DMSO (Invitrogen). The tube was 
packed in tinfoil and rotated for one hour before the bacteria were washed three times, 
resuspended in PBS and counted as described above. 
The purified LPS used in paper I was extracted from 44/76 by the phenol extraction method
(121).
3.2 Analyses
3.2.1 Quantification of bacterial concentrations  
DNA was isolated with robotized equipment (BioRobot 48; Qiagen Inc, Valencia, CA) based 
on absorbance to magnetic silicia particles (MagAttract DNA Blood M96 kit 951436;
Qiagen). Genome quantification of N. meningitidis was performed by quantitative real-time
PCR (LightCycler; Roche Diagnostics GmbH, Mannheim, Germany) based on detection of 
the meningococcal capsular transfer gene (ctrA) (23,122). Lower detection limit of the assay 
was 1x103/mL. In paper II the numbers of live N. meningitidis in whole blood were also 
determined by plating ten-fold dilutions of whole blood, and counting plates with 25-250 
colony forming units (CFUs) after 24 hours growth.
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3.2.2 Quantification of LPS
LPS concentrations were determined by the Pyrochrome® Limulus Amoebocyte Lysate
(LAL) assay (Associates of Cape Cod, East Falmouth, MA), an endpoint chromogenic 
method using a diazo-coupling assay kit. The samples were diluted in depyrogenated 
Pyrotube-D tubes with LAL Reagent water. The diluted samples were heat-treated at 75°C 
for 10 minutes, mixed with Pyrochrome dissolved in a Glucashield -glucan inhibiting 
buffer, and incubated in a 96-well Pyroplate on a dry block incubator. After incubation, the 
procedure was followed according to the instructions from the manufacturer. Lower detection 
limit of the assay was 3.13 EU/mL.
3.2.3 Complement activation
TCC was measured in EDTA plasma by ELISA (123). The assay is based on a monoclonal 
antibody (aE11) recognizing a neoepitope exposed in C9 after it has been inserted in the 
TCC. Values are given in arbitrary units (AU) defined by a serum standard activated with 
zymosan and defined to contain 1000 AU/mL.
3.2.4 Quantification of inflammatory mediators
In paper I TNF-, IL-1, IL-6 and IL-8 were measured in EDTA plasma on a Bio-Plex Array 
Reader (LUMINEX 100, Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Human 
Cytokine panel. 
In paper IV and V TNF-, IL-1, IL-6, IL-8 and IL-12 were analyzed in EDTA plasma with
porcine ELISA kits (R&D Systems, Minneapolis, MN). IL-10 was analyzed in EDTA 
plasma with BioSource Swine Immunoassay Kit (Invitrogen, Carlsbad, CA). VEGF was 
analyzed in EDTA plasma by a R&D Quantikine Human Immunoassay kit (R&D Systems, 
Minneapolis, MN), known to cross-react with porcine VEGF (124). 
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3.2.5 Transient transfection and luciferase assay
In paper I Human embryonic kidney (HEK) 293 cells (ATCC) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% heat inactivated fetal calf serum 
(Euroclone, Milano, Italy), L-glutamine and 10 *g/mL ciprofloxacin (Cellgro, Manassas, 
VA) at 37oC and 8% CO2. Transient transfection was done using GeneJuiceTM transfection 
reagent (Novagen, Merck KGaA, Darmstadt, Germany) according to the manufacturer’s 
protocol. In short, cells were plated at a cell density of 1x104 cells/well in 96-well dishes and 
grown to 50% confluency. Plasmids used were the NF-!B dependent luciferase reporter 
plasmid pELAM-luc (125), human CD14 in pcDNA3 kindly provided by Dr. D. Golenbock 
(University of Massachusetts Medical School), human MD-2 in pEFBOS kindly provided by 
Dr. K. Miyake (University of Tokyo), human TLR4 in pcDNA3 kindly provided by Drs. R. 
Medzhitov and C. Janeway (Yale University, New Haven, CT), and human TLR2 in pRK7 
kindly provided by Dr. C. Kirschning (Technical University of Munich). Each plasmid was 
transfected at a dosage of 25 ng/well and pcDNA3 (Invitrogen) was used to adjust the total 
amount of plasmid to 100 ng/well. All plasmids were isolated using the EndoFree plasmid kit 
(Qiagen Inc., Valencia, CA). The cells were incubated for 24 hours before the experiments 
were performed as described later. HEK293 cells stably transfected with TLR9 were
provided by Eisai Pharmaceuticals (Andover, MA). The positive controls were stimulated 
with 10*M phospothioate CpG DNA 2006 (Tib Molbiol, Berlin, Germany). Cytoplasmic 
extracts were prepared and luciferase activity was measured using the Luciferase Assay 
System kit according to the manufacturer’s recommendations (Promega, Madison, WI) and 
Victor3TM 1420 multilabel counter (PerkinElmer, Waltham, MA). Results from triplicate 
wells (duplicate for the TLR9 transfected cells) are given as fold induction relative to PBS 
treated negative control.
3.2.6 Opsonophagocytic activity (OPA) and oxidative burst
In paper II OPA was measured as oxidative burst in granulocytes using live meningococci 
(126). The bacteria were grown on Colombia horse blood agar for about 18 hours at 37C in 
5% CO2 before suspension in HBSS (pH 7.2) with 0.1% bovine serum albumin. Two-fold 
dilution series of the various serum samples were mixed with meningococci and incubated 
for 30 minutes at 37oC under agitation. In some of the experiments the bacteria were first 
incubated with heat inactivated serum, followed by 10 minutes incubation with a separate 
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complement source. Granulocytes from heparinized whole blood where the red cells were 
removed by ammonium chloride lysis were primed with dihydrorhodamine 123 (Invitrogen) 
and finally added before incubation continued for another 10 minutes. The results were 
measured by a CyFlow ML flow cytometer (Partec GmbH, Münster, Germany), looking 
for fluorescence within the granulocyte population. The percentage oxidative burst positive 
granulocytes were recorded and OPA titers were expressed as the reciprocal of the final 
serum dilution giving oxidative burst in +,-.
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In paper III phagocytosis by granulocytes and monocytes was measured as internalization of 
the bacteria using the Phago test kit (Orpegen Pharma, Heidelberg, Germany). Alexa-stained 
bacteria were incubated in lepirudin anticoagulated whole blood for 10 minutes and the 
blood was then processed according to kit instructions. Quenching solution was used to avoid 
interference of surface-bound bacteria (127). In these experiments phagocytosis was 
expressed as median fluorescence intensity (MFI) of the whole granulocyte or monocyte 
population. Samples were analyzed on a LSRII flowcytometer (Becton Dickinson).  
Oxidative burst was measured separately using the Burst test kit (Orpegen Pharma). Whole 
blood samples were incubated with bacteria for 10 minutes before dihydrorhodamine 123 
was added and incubation continued for another 10 minutes. The samples were then lysed 
and washed according to kit instructions and oxidative burst in granulocytes and monocytes 
was measured by flow cytometry. Results were expressed as MFI of the whole gated cell 
population.
3.2.7 CD11b expression
In paper II the expression of CD11b on granulocytes was measured by the CyFlow ML 
flow cytometer (Partec GmbH) by using a mouse anti-human CD11b antibody (Serotec, 
Dusseldorf, Germany).
3.2.8 Serum bactericidal activity (SBA)
SBA was measured in paper II using meningococci grown overnight at 37°C in 5% CO2. The 
overnight growth was plated onto Colombia horse blood agar plates and incubated for four
hours to reach log phase before suspension in HBSS (pH 7.2) with 0.1% bovine serum 
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albumin (128). Then, 25% human serum was added as an exogenous source of human 
complement. Heat-inactivated sera known to contain specific antibodies against the target 
strain were diluted two-fold in microtiter plates (starting at a serum dilution of 1:2) and 
incubated for 30, 60, and 90 min at 37°C in air with bacteria and complement. After plating
onto agar plates and incubation overnight at 37°C, CFU were counted with Sorcerer colony 
counter (Perceptive Instruments, Suffolk, United Kingdom), and SBA antibody titers were
expressed as the reciprocal of the final serum dilution giving +50% killing of inoculum 
compared to controls.
3.2.9 Flow cytometry of erythrocytes carrying bacteria and free bacteria in plasma 
In paper III the proportion of bacteria being adherent to erythrocytes and free in plasma was 
measured in whole blood incubated with Alexa-stained E. coli or N. meningitidis. The 
bacteria were fixed with 0.25% (v/v) PFA for four minutes at 37C. Samples were then 
diluted 1:320 with PBS in Truecount tubes to avoid coincidences with erythrocytes not 
carrying bacteria. Whole blood added 10 mM EDTA served as a control for coincidences. 
Samples were run on a FACSCalibur or LSRII flow cytometer (Becton Dickinson).  Gates 
were set around the beads, the erythrocytes and the free bacteria and calculations were made. 
The erythrocyte population was verified in control experiments using anti-Glycophorin A 
(Dako, Glostrup, Denmark). To verify that the bacteria/erythrocyte-conjugates did not appear 
because of PFA we performed control experiments without PFA and similar results were 
obtained.
3.2.10 Flow cytometry of bacterial opsonization
In paper III C1q, C3 and C4 opsonization of E. coli and N. meningitidis was analyzed by 
flow cytometry using rabbit anti-human C1q, FITC-conjugated rabbit anti-human C3c 
(F0201) and rabbit anti-human C4c mAbs, respectively. FITC-conjugated rabbit anti-mouse 
Ig was used as control. All antibodies were from Dako. Results are expressed as MFI.
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3.2.11 Microscopy
In paper III smears of whole blood incubated with Alexa-stained E. coli and N. meningitidis 
was examined using either the transmitted light observation microscopy or the reflected 
fluorescence procedure using appropriate filter for Alexa. Combined reflected fluorescence 
and transmitted light was performed according to the microscope instructions using very 
weak transmitted light intensity. The Olympus BX51TRF microscope (Olympus, Tokyo, 
Japan) was equipped with a ColorView IIIu digital camera with 5 megapixel resolution and 
was controlled by the CellP program (Soft imaging system, Münster, Germany).
Immunofluorescence histology was performed on cryosections obtained from the lung, liver 
and spleen of the pigs given Alexa-stained E. coli. Cryosections (5 µm thick) were cut from 
tissue embedded and snap-frozen in O.C.T Compound (Tissue-Tek; BDH, Lutterworth, UK). 
Sections were air dried and fixed for 10 minutes in ice-cold acetone. Fc receptors were 
blocked by incubating the sections for 30 minutes with PBS containing 5% pig serum and 5% 
goat serum. To identify tissue macrophages, a pretitrated anti-porcine CD45 monoclonal 
antibody (a kind gift from Karin Haverson, University of Bristol, Bristol, UK) was applied 
and incubated for two hours. Slides were washed thoroughly three times with PBS for five
minutes. An isotype-specific goat anti-mouse antiserum (Southern Biotechnology,
Birmingham, AL) conjugated to Texas Red was then applied and incubated for one hour. The 
slides were washed three more times, and the nuclear dye DAPI was applied and incubated 
for 10 minutes. After a final wash, the sections were mounted in Fluoromount (Vector 
Laboratories, Burlingame, CA) and sealed with nail varnish. Stained slides were examined 
using a Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan) fitted with a combined
excitation and emission filter block specific for the applied fluorescence staining.
3.2.12 Hematological parameters
In paper IV and V hematological parameters were analyzed by the hospital’s routine 
hematology laboratory (CELL-DYN 4000 flowcytometer, Abbot Diagnostics, IL). 
Neutrophil granulocytes were fully discriminated, but monocytes and lymphocytes merged 
as one cell population designated mononuclear leukocytes.
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3.2.13 Hemostatic parameters
In paper IV and V thrombin activation was measured in citrate plasma as thrombin-
antithrombin complex (TAT) by a human ELISA kit known to cross-react with porcine TAT 
(Dade Behring, Marburg, Germany) (129). Plasminogen activator inhibitor 1 (PAI-1) was 
measured by a porcine PAI-1 activity ELISA (Molecular Innovations, Novi, MI).
3.2.14 Capillary leakage
In paper IV and V the amount of protein leakage out of the intravascular compartment was 
estimated by calculating the relative changes of albumin content in plasma from the starting 
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– AlbuminT0}/AlbuminT0] x 100. The amount of fluid accumulation in the tissues was 
estimated by wet/dry ratio. A muscle biopsy was taken at 0 and 240 minutes, and biopsies 
from both lungs and the jejunum were taken at 240 minutes. All biopsies were placed in pre-
weighed containers. The biopsies were then weighed and dried at 70o C until stable weight 
before the wet/dry ratio was calculated.
3.3 Experimental models used in the thesis
3.3.1 Complement activation in serum 
In paper I complement activation in serum by NmLPS+ at increasing concentrations was 
examined. Based on preliminary experiments with 10-fold increasing concentrations, the 
concentration of NmLPS+ was increased two-fold from 1x106 to 5x108 bacteria/mL. Sera 
from three of the donors were activated simultaneously with NmLPS- at similar 
concentrations and conditions. Additional experiments were also performed with NmC at
similar concentrations in sera from three of the donors. Serum was activated by the bacteria 
for 30 minutes at 37oC before further activation was stopped by placing the samples on ice 
and adding EDTA. The serum was then frozen at – 70oC until analysis for complement 
activation by soluble terminal C5b-9 complement complex (TCC). TCC was chosen as
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readout because it reflects overall complement activation well and we possess a well 
established kit for this analysis. ELISA analysis was also performed with the C3 split 
product C3bc in some of the samples. The results were similar to TCC but the background 
concentrations were higher. Thus, only TCC was used in the paper. 
3.3.2 Inflammatory responses in whole blood
In paper I cytokines and complement activation were measured in lepirudin anticoagulated 
freshly drawn whole blood from healthy donors incubated with NmLPS+, NmLPS- and 
NmC at 10-fold increasing concentrations from 1x103 to 1x108 bacteria/mL. Lepirudin was 
used as anticoagulant as this substance inhibits thrombin specifically, and thus all biological 
systems apart from the final coagulation step are left functionally intact (127). The 
experiments were performed without inhibition, with a CD14 blocking antibody (ATCC 
Number HB-247) and an isotype mAb, and with complement inhibition by compstatin or a 
C5aR peptide antagonist (131). The peptide compstatin blocks complement activation by 
binding to C3 and thus, inhibit cleavage of this key complement factor (132). CD14 and 
complement was blocked separately and simultaneously. The number of donors included was
eight for NmLPS+ at 105 – 107 bacteria/mL, five for other concentrations of NmLPS+ as 
well as NmLPS- and three for NmC. After 2 hours incubation with bacteria at 37oC the 
samples were placed on ice before EDTA was added to stop further reactions. Plasma was 
then collected after centrifugation and frozen at -70oC for later analysis. 
3.3.3 The role of individual TLRs and CD14 in the inflammatory response induced by 
N. meningitidis 
In paper I the specific role of key receptors for stimulation of the cellular innate immune 
system was examined by the activity of NF-!B in HEK293 cells expressing TLR4/MD-2
with and without CD14, TLR2 with and without CD14, and TLR9. The transfected HEK293 
cells were incubated with NmLPS+ or NmLPS- at 10-fold increasing concentrations from 
1x104 to 1x108 bacteria/mL or purified LPS at 10-fold increasing concentrations from 0.1 
#89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– 14000 EU/mL) for 18 hours. HEK293 cells expressing TLR9 were 
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NF-!B activity was then measured by a 
luciferase assay after lysis of the cells (125).
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3.3.4 Survival and proliferation of N. meningitidis in whole blood deficient of 
complement factors C2, C5 and MBL
In paper II the influence of different parts of the complement system on the survival and 
proliferation of meningococci in whole blood was examined by adding an inoculum of 105
live meningococci/mL to lepirudin anticoagulated blood freshly drawn from donors 
genetically deficient of C2 and C5/MBL. Parallel experiments were performed with blood 
reconstituted with the deficient factors and blood from two control donors, of which the 
control donor matching the C5/MBL deficient donor was also deficient of MBL (133).
Meningococci were incubated in the blood for time intervals ranging from 10 minutes to 24 
hours before samples were withdrawn for analysis of CFU and genome DNA quantification 
with quantitative real-time PCR.  Two similar experiments were performed on two 
consecutive days.
3.3.5 Influence of complement and antibodies on phagocytosis 
In paper II the influence of complement and antibodies on OPA was analyzed by using 
serum from the complement deficient donors and the matching controls. Three different 
protocols were examined. First, experiments were performed using two-fold titration of test 
sera (complement-deficient, reconstituted, and control sera) to reveal the OPA of test sera 
depending on its own IgG and complement content. The second protocol entailed two-fold 
titration of heat-inactivated test sera following the addition of 10% homologous serum passed 
through a protein G column to remove IgGs to provide fixed amount of complement. By 
using this approach, uncertainty about whether antibodies or complement was the limiting 
factor at higher dilutions was avoided, since the complement concentration was kept 
constant. The third protocol consisted of two-fold titration of heat-inactivated serum from a 
subject immunized with a N. meningitidis 44/76 outer membrane vesicle vaccine using each 
of the test sera preparations as the complement source (10%) after passing them through a 
protein G column. By this method, the antibody coating of the meningococci was 
standardized.
3.3.6 Influence of cell preparation on the expression of CD11b on granulocytes
In paper II heterologous granulocytes were used in the OPA experiments. A previous study 
showed no up-regulation of CD11b on the surface of granulocytes from the C5 deficient 
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donor when whole blood was incubated with bacteria, and consequently no phagocytosis 
(133). As phagocytosis apparently occurred in the present study also with serum from the C5 
deficient donor, we examined whether handling of the heterologous granulocytes ex vivo up-
regulated CD11b before they were stimulated by the bacteria. CD11b expression on 
granulocytes was measured in whole blood kept at 4oC and after preparation of the 
granulocytes, as used in the OPA assay.
3.3.7 Influence of complement and antibodies on SBA
In paper II the influence of complement and antibodies on SBA was examined by using 
serum from the complement deficient and the matching controls in the SBA assay. The 
complement deficient sera, reconstituted sera, sera from the two matching control donors or 
serum from an individual known to have all complement factors intact but no SBA 
antibodies were used as exogenous sources of complement. Heat-inactivated sera known to 
contain specific antibodies against the target strain 44/76 or a monoclonal antibody against 
the P1.16 epitope of this strain were diluted two-fold and then incubated with bacteria and 
complement. CFU were counted after plating onto agar plates and incubation overnight, and 
SBA antibody titers were expressed as the reciprocal of the final serum dilution giving +50% 
killing of inoculum compared to controls.
3.3.8 Binding of Gram-negative bacteria to erythrocytes and the influence of such 
binding on phagocytosis and oxidative burst 
In paper III binding of Alexa-stained E. coli and N. meningitidis (NmLPS+) to erythrocytes,
phagocytosis in granulocytes and monocytes and oxidative burst in granulocytes were 
analyzed by flow cytometry after incubation of the bacteria in lepirudin anticoagulated whole 
blood. First, the dose-response effect of E. coli binding to erythrocytes, phagocytosis and 
activation of complement was investigated by adding increasing doses of E. coli to the blood 
and incubate for 10 minutes. Next, the role of complement on the binding of E. coli and 
N. meningitidis to erythrocytes and phagocytosis was investigated by adding bacteria to the 
blood and incubate for 10 minutes in the presence of mAbs blocking complement factors C2 
and factor D (anti-C2/D) and an isotype control mAb (134), the C5aR antagonist also used in 
paper I and its corresponding control peptide or EDTA. The experiments with                     
N. meningitidis were also performed with compstatin as a complement inhibitor. 
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Subsequently time course experiments of E. coli binding to erythrocytes and granulocyte 
phagocytosis were performed with up to 120 minutes incubation of the bacteria in whole 
blood to investigate the dynamic interaction between binding of the bacteria to erythrocytes 
and phagocytosis. To further investigate the role of complement in these processes the 
experiments were also performed with complement inhibitors compstatin and the C5aR 
antagonist. The role of complement receptor CR1 in the binding of E. coli and                     
N. meningitidis to the surface of erythrocytes were then investigated by incubating the 
bacteria in blood with the CR1 blocking antibody mAb 3D9 (135). Dose-response 
experiments were performed initially with increasing doses of the antibody present in blood 
incubated with a fixed concentration of E. coli (7.2x107 bacteria/mL). Phagocytosis and 
oxidative burst were analyzed in granulocytes from the same experiments to examine the 
effect of bacteria binding to CR1 on these mechanisms. Finally, experiments with an optimal 
dose of the CR1 blocking antibody present was performed with E. coli, NmLPS+ and 
NmLPS- to examine the influence of CR1 on the binding of the two Gram-negative bacteria, 
and the influence of LPS. 
3.3.9 Complement mediated opsonization of E. coli and N. meningitidis 
In paper III opsonization of E. coli and N. meningitidis with deposition of complement 
opsonins C3b and C4b on the surface of the bacteria was analyzed using flow cytometry after 
the bacteria were incubated 10 minutes in lepirudin plasma. The experiments were also 
performed with compstatin and the C5aR antagonist as complement inhibitors. 
3.3.10 Microscopy of whole blood smears
In paper III human whole blood was supplemented with PBS containing Alexa-stained        
E. coli or N. meningitidis (7.2 x 107/mL final concentration) and incubated 10 min at 37oC. 
Whole blood smears were then made and immediately air dried. As a control, a portion of the 
whole blood was diluted with PBS and examined as wet preparation by fluorescence 
microscopy. The smears were stored in the dark before they were examined using the 
transmitted light observation microscopy or the reflected fluorescence procedure alone or in 
combination as previously described.  
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3.3.11 Porcine model of meningococcal sepsis
The experiments were performed in adherence to the Norwegian laboratory animal 
regulations and the study protocol was approved by the University Animal Care Committee. 
Norwegian landrace pigs of either sex with a body weight of 30 ± 2.5 kg were investigated. 
The pigs were kept in the animal department with free access to water for one day ahead of 
the experiments. Ketamine (20 mg/kg), atropine (1 mg), and azaperone BPVet (80 mg) were 
given intramuscularly to induce anesthesia. Supplementary doses of pentobarbital sodium 
and morphine were administered intravenously through an ear vein to obtain surgical 
anesthesia. The pigs were tracheotomized in supine position and 1% isoflurane in air-oxygen 
inhalation anesthesia was administered through a Siemens Kion anesthesia apparatus. 
Respirator settings were adjusted to maintain a pH of 7.40 and arterial oxygen saturation 
above 94%. A 16F pulmonary artery catheter with heating filament and pulse oximetry for 
recording of continuous cardiac output, central venous oxygen saturation, central venous 
pressure (CVP) and pulmonary artery occlusion pressure (PaOP) (Baxter Edwards 
Laboratories, Irvine, CA), was inserted via the right external jugular vein and guided into a 
distal pulmonary artery by pressure wave-form analysis. Pressure transducers were zero 
referenced to mid-chest level. Three central venous lumina of the pulmonary artery catheter 
introducer were used for volume therapy, continuous infusion of 1 mg/kg/h morphine, and 
0.5 mg/kg/h of the muscle relaxant vecuronium bromide. A Secalon® T (18G, 1.2X90 mm) 
was inserted in the right common carotid artery for intermittent blood sampling and 
continuous recording of arterial pressure. A urinary catheter for continuous urinary output 
measurements was inserted through an open cystostomy. A patient warmer (Warm Touch, 
DRE, Inc. Louisville, KY) and pre-warmed Ringer’s acetate (RA) were used to maintain a 
core temperature of 38-39ºC. After surgery, the animals were placed in the right lateral 
position and allowed to stabilize. During the 60-90 minutes of surgery and stabilization, and 
before the start of the experiments, the animals received 30 mL/kg RA as volume therapy to 
compensate for a fluid deficit caused by transport and the acclimatization period.
After the stabilization period, the pigs were randomly allocated into the respective study 
groups. Heat inactivated meningococci were infused intravenously at exponentially 
increasing rate from a starting dose estimated in pilot experiments, doubling the infusion rate 
every 30 minutes during 4 hours. All pigs received Ringer acetate (RA) 180 mL/hour. The 
sepsis pigs were given RA 1000 mL/hour in addition and extra bolus infusions when needed 
to keep mean arterial pressure (MAP) above 65 mmHg. Norepinephrine was also 
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administered intravenously in cases of volume refractory hypotension. Physiological data 
were registered and blood samples drawn at 0, 30, 60, 120, 180 and 240 minutes. 
Hemodynamic data were recorded from Edwards Vigilance Monitor (Baxter Edwards 
Laboratories, Irvine, CA) and Drägers Infinity Delta (Dräger Medical, Lübeck, Germany). 
Respiratory and anesthesiological data were from Siemens KION and the Sc9000XL 
Monitor (Siemens, Erlangen, Germany). Extended blood gas parameters were recorded from 
Radiometer ABL800 Flex (Radiometer, Copenhagen, Denmark). At the end of the 
experiments the animals were euthanized by intravenous injection of 500-1000 mg 
pentobarbital, 30 mg morphine and 40 mmol potassium chloride. After the animals were 
dead biopsies from selected organs were taken for later analysis of wet/dry ratio, 
quantification of bacterial numbers by real-time PCR and LPS content by LAL-assay, 
immunhistology, cytokines and studies of gene transcription by micro array and real-time 
PCR. 
In paper IV a total number of 10 pigs were included in the sepsis group. All pigs were given 
NmLPS+, of which five pigs received 5.7x1010 and five pigs received 1.1x1011 bacteria in 
total. Six pigs were included in a control group which did not receive bacteria, but an 
equivalent amount of 0.9% sodium chloride. Three additional pigs, not receiving bacteria, 
were examined to exclude a possible effect of volume therapy and norepinephrine treatment 
by itself. Two of the three pigs received the same volume of RA as in the sepsis group, and 
the third pig received escalating doses of norepinephrine over four hours reaching 0.54 
*g/kg/minute for the last hour.
In paper V two groups of eight pigs each received NmLPS+ or NmLPS- intravenously. In 
order to examine differences dependent on bacterial load, pigs received various total 
numbers of meningococci and were matched into pairs where the two pigs in each pair 
received equal numbers of either NmLPS+ or NmLPS-. A total of 5.7 x 1010 meningococci 
was administrated to the pair receiving the lowest numbers of bacteria; the successive pairs 
received two-fold, three-fold, four-fold, five-fold, six-fold, 10-fold and 20-fold this number 
of meningococci. Two pigs serving as negative controls received only 0.9% soidum chloride.
Six additional similar pigs from the previous study served as historical reference controls. 
In paper III four pigs were also included to supplement the in vitro experiments. Two of the 
pigs received Alexa-stained E. coli and the remaining two pigs received Alexa-stained        
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N. meningitidis. A total amount of 5.7 x 1010 heat-inactivated bacteria were infused 
intravenously during the first 120 minutes.  The initial bacteria dose was 4.5 x 108
bacteria/hour and the infusion rate was doubled every 30 min up to 120 min. After 120 min, 
a bolus containing 9.2 x 1010 bacteria was injected during approximately one minute.
Thereafter the pigs were observed for a maximum of one hour or until death. In addition to 
the routine analysis, blood samples were taken during the experiment for bacterial genome 
quantification by real-time PCR in whole blood, plasma, buffy coat and erythrocyte 
fractions. Also, whole blood smears were prepared for microscopy as described previously.
3.3.12 Statistical considerations
Parametric statistics was applied to compare the groups in paper I, III, IV and V as the data 
passed criteria for normal distribution. No statistics was applied to the data in paper II and 
the experiments with HEK293 cells in paper I, as the character of these experiments with a 
couple of parallel experiments “speaking for themselves” did not warrant statistical analysis 
to be performed (133).
When two groups were statistically compared the Student’s t-test was performed, as when 
the effect of the two complement inhibitors compstatin and the C5aR antagonist was 
compared in paper I and the wet/dry ratios were compared in the porcine model studies. 
Paired t-test was used when parallel results were obtained from the same individual, while 
unpaired t-test was used when results were obtained from different individuals.  
When more than two groups were statistically compared ANOVA was used. Repeated 
measurement ANOVA was used when the results compared was obtained from the same 
individual. This applied to most of the results in paper I, where also Bonferroni post-test 
analysis was performed. The ANOVA analysis of the inhibition studies in that paper had to 
be performed separately at each bacterial concentration included, while the analysis of the 
cytokine response after incubation with NmLPS+ and NmLPS- without inhibition was 
performed as an overall analysis with two-way ANOVA. In paper III repeated measurements 
ANOVA with Holm-Sidak post-test analysis was performed. In paper IV and V repeated 
measurements ANOVA was applied to include the whole time course in the same analysis. 
As the experimental set-up in paper V consisted of three individual groups receiving 
NmLPS+, NmLPS- and the control group, respectively, it would be desirable to include a 
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post-test analysis to separate significant effects by each of the groups by using only one test. 
However, we decided to use covariates in the analysis to account for different baseline values 
of several parameters at the beginning of the experiments influencing the later results, and 
also to account for different numbers of bacteria given to individual pigs. Thus, post-test 
analysis could not be performed. Instead, two separate tests were performed for each 
parameter to allow for identification of LPS-specific effects by comparing the groups given 
NmLPS+ and NmLPS- and to allow for identification of effects by non-LPS structures of the 
meningococci by comparing the group given NmLPS- and the control group. A professional 
statistician approved this way of applying the analyses.
In general a two-tailed p of <-$-,)	#$
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4 Summary of the main results
4.1 Paper I
This paper demonstrates dose-dependency of complement activation and cytokine secretion 
with increasing numbers of N. meningitidis. Also, the study describes how different 
inflammatory mechanisms operate with different numbers of N. meningitidis present. 
Complement activation by means of soluble TCC in serum increased to a significant 
threshold at 3x107meningococci/mL and as the bacterial concentration was increased further 
TCC increased dose-dependently. All three strains investigated, i.e. NmLPS+, NmLPS- and 
NmC activated complement to the same extent. 
Pro-inflammatory cytokine secretion in whole blood incubated with NmLPS+ and NmC 
started to increase at 103 – 104 bacteria/mL. There was a dose-dependent increase in 
cytokines with increasing bacterial concentrations up to 107 bacteria/mL.  The threshold for 
cytokine secretion in whole blood incubated with NmLPS- was 107 bacteria/mL and the 
secretion increased substantially when the concentration of NmLPS- was increased to 108
bacteria/mL.
Inhibition of CD14 reduced the cytokine secretion induced by NmLPS+ and NmC to 
baseline levels at bacterial concentrations up to 106/mL. At higher bacterial concentrations 
the cytokine secretion was still reduced substantially by inhibition of CD14. IL-6 proved to 
be most dependent on CD14 as the secretion was reduced by 90% at 106 and 70% at 107
bacteria/mL while IL-8 proved to be least dependent on CD14 as the secretion was reduced 
by 60% at 106 and 35% at 107 bacteria/mL. Inhibition of CD14 when NmLPS- was incubated 
in whole blood also had most effect on IL-6 being reduced by 60% at 107 and 108
bacteria/mL, and least effect on IL-8 being reduced only at 108 bacteria/mL (20%). 
Complement inhibition in blood incubated with NmLPS+ and NmC influenced the cytokine 
secretion at bacterial concentrations from 105 to 107/mL. IL- '=-9-8 was most 
dependent on complement and was reduced up to 40%, while IL-6 was not influenced 
significantly by complement inhibition. IL- '=-9-8 were also most dependent on 
complement inhibition when whole blood was stimulated with NmLPS-. The effect of 
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complement inhibition was relatively larger with NmLPS- than with NmLPS+ and NmC. 
Complement inhibition at the C3 level by compstatin had equal effect as C5aR inhibition. 
Combined inhibition of CD14 and complement in blood incubated with NmLPS+ and NmC 
reduced cytokine secretion more than either of the inhibitors alone at 106 and 107
bacteria/mL.  At 106 bacteria/mL the secretion of cytokines was almost completely abolished 
by the combined inhibition while at 107 bacteria/mL the secretion was reduced by 60 to 80%. 
In blood incubated with NmLPS- the combined inhibition reduced the cytokine secretion by 
50 to 70% at 107 bacteria/mL and by 70-90% at 108 bacteria/mL.
Activation of transfected HEK293 cells expressing TLR4/MD2 and CD14 with NmLPS+ up-
regulated NF-B activity dose dependently from 104 to 108 bacteria/mL while incubation of 
cells expressing TLR4/MD2 without CD14 up-regulated NF-B activity only at 107 and 108
bacteria/mL. At 108 bacteria/mL CD14 had no influence on NF-B activation. Activation of 
HEK293 cells expressing TLR2 and CD14 in combination or TLR2 without CD14 up-
regulated NF-B activity equally and dose dependently from 107 to 108 bacteria/mL.
Activation of cells expressing TLR9 induced only negligible up-regulation of NF-B
activity. 
HEK293 cells were only activated by NmLPS- when expressing TLR2. Additional 
expression of CD14 did not influence the NF-B activation by NmLPS- and no up-regulation 
of NF-B activation was seen in cells with TLR4/MD2 or TLR4/MD2 and CD14. 
When HEK293 cells expressing TLR4/MD2 and CD14 was activated by purified                 
N. meningitidis LPS there was an almost equally high response throughout the whole range 
of LPS concentrations while a dose dependent response became evident when cells 
expressing TLR4/MD without CD14 was activated by LPS. 
4.2 Paper II
This paper demonstrates critical roles of C2 and C5 in the major defense mechanisms against 
meningococci, i.e. phagocytosis and serum bactericidal activity. Also, the study demonstrates 
how the level of anti-meningococcal antibodies can influence these two defense mechanisms 
differently. 
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When meningococci were incubated in C2- and C5-deficient whole blood the number of 
bacteria increased throughout the incubation period with final increase in CFU of ~2 log10
and a final increase in the number of DNA copies of 4 to 5 log10. When meningococci were 
incubated with reconstituted C2-deficient blood and with blood from either of the two 
control individuals, the number of CFU initially decreased ~2 log10 but after two hours 
started to increase, ending up with similar numbers of bacteria as with the C2- and C5-
deficient blood. When meningococci were incubated with reconstituted C5-deficient blood 
no CFU was detected after two hours and, accordingly, there was no increase in the numbers 
of DNA copies. 
Granulocytes incubated with C2-deficient serum had no detectable OPA while C2 
reconstitution restored OPA to the level of the C2 control. Granulocytes incubated with C5-
deficient serum had high OPA, similar to the level seen after reconstitution with C5 and 
MBL and the OPA seen with the positive control (post-vaccination serum). OPA with serum 
from the C5 control individual, being MBL-deficient like the C5-deficient individual, was 
similar to the OPA seen with the reconstituted C2-deficicent serum, i.e. lower than the OPA 
seen with serum from the C5-deficient individual. Reconstitution with MBL had no effect on 
OPA. 
When standardizing the amount of complement factors in all titrations by first titrating heat-
inactivated sera against meningococci and then adding a fixed volume of IgG-depleted 
homologous serum as the complement source, similar results were obtained as in the 
previous experiments where native sera were titrated against meningococci, i.e. absence of 
OPA only with the C2-deficient serum. 
When the amount of antibodies was kept equally high inn all experiments by titrating heat-
inactivated postvaccination serum against meningococci before adding IgG-depleted test sera 
as the complement source, the OPA-titer was similarly low with the C2-deficient serum as in 
the negative control where complement was absent. The other test sera had increased OPA, 
being equally high with all different sera. 
Notably, we found that CD11b was spontaneously up-regulated on the heterologous 
granulocytes used in this experiment when the cells were prepared including lysis of the 
whole blood. 
SBA was not observed with any of the native test sera. However, after reconstitution of the 
C5-deficient serum SBA was markedly increased. MBL reconstitution had no effect on SBA. 
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When serum without antibodies was added to heat-inactivated test sera titrated against 
meningococci, SBA was also markedly increased only with the C5-deficient serum. 
Experiments were also performed with the C2-deficient serum in the presence of high levels 
of anti-meningococcal antibodies to investigate whether SBA could occur under such 
conditions by a C2-bypass mechanism. We found no evidence for such a mechanism to 
occur. 
4.3 Paper III
This paper demonstrates binding of Gram-negative bacteria to erythrocyte CR1 and that such 
binding reduce phagocytosis and oxidative burst. 
Approximately 80% of E. coli and N. meningitidis added to human whole blood were bound 
to erythrocytes after 10 minutes incubation. Dose-response experiments showed a linear 
relationship between the concentrations of E. coli and the number of free bacteria in plasma 
and bacteria bound to erythrocytes. A non-linear relationship between the pahgocytosis of 
E. coli and the added bacteria concentration was found. There was a linear relationship 
between the number of E. coli added and complement activation measured by TCC. 
Fluorescence microscopy of blood smears confirmed binding of E. coli and N. meningitidis 
to erythrocytes. When microscopy was performed on diluted whole blood in wet fluid 
preparations, the bacteria were mainly found on erythrocytes, moving with the bacteria 
bound to their surface. 
Complement inhibition by anti-factor C2/D or compstatin significantly reduced the binding 
of bacteria to erythrocytes and simultaneously increased the number of free bacteria in 
plasma. Complement inhibition with the same inhibitors also completely blocked 
phagocytosis after 10 minutes incubation. Inhibition with the C5aR antagonist did not 
influence the binding of bacteria to erythrocytes but blocked phagocytosis by granulocytes 
completely by monocytes partially after 10 minutes incubation.  
Time course studies showed that the binding of bacteria to erythrocytes was time-dependent 
and slowly decreased with time, although most bacteria were still bound after two hours. 
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Compstatin increased the release of bacteria from erythrocytes. Phagocytosis by granulocytes 
was initially completely inhibited by compstatin and the C5aR antagonist, but subsequently 
increased. 
C3 opsonization of E. coli and N. meningitidis was efficiently reduced by compstatin, 
whereas C4 opsonization increased. LPS had no effect on the opsonization, as the wild-type 
N. meningitidis and the LPS-deficient mutant strain were equally opsonized. 
The anti-CR1 blocking antibody dose-dependently decreased the binding of E. coli and       
N. meningitidis to erythrocytes and simultaneously increased the number of free bacteria in 
plasma. At the same time phagocytosis and oxidative burst by monocytes and granulocytes 
also increased when binding to CR1 was inhibited. LPS had no effect on the binding to CR1, 
as the wild-type N. meningitidis and the LPS-deficient mutant strain behaved equally.
In the in vivo experiments with the porcine sepsis model five minutes after the bolus 
injection of bacteria 24% of E. coli was located to the erythrocyte fraction while 42% was in 
plasma and 34% was in the buffy coat fraction. Approximately one hour later 14% was in the 
erythrocyte fraction while 30% was in plasma and 56% was in the buffy coat. 
Immunofluorescence histology of the lungs, spleen and liver from the pigs showed that the 
Alexa-bacteria were mainly located in the lungs. The distribution of N. meningitidis in vivo 
was equal to E. coli.
4.4 Paper IV
The main achievement of this paper was to establish a large animal model of meningococcal 
sepsis being suitable to study pathophysiological and immunological aspects of this disease 
experimentally in vivo, and which also could be used for possible experimental therapeutic 
interventions. 
Of cardiovascular parameters MAP was kept stable during most of the observation period by
intensive fluid resuscitation, but gradually declined towards the end, simultaneously with a 
decline in SVRI. An abrupt and prominent rise in PVRI and mean MPAP was seen
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approximately 30 – 45 minutes after start of bacterial infusion. Lactate increased 
significantly.
The intravascular albumin content in the sepsis group decreased substantially during the 
course of the experiment and the final plasma albumin content was only about 50% of the 
initial content. The wet/dry ratio in muscle increased significantly from start to end of the 
experiment in the sepsis group and the wet/dry ratio in the gravity dependent right lung (all 
pigs were in the right decubital position) and jejunum differed significantly between the 
sepsis and the control group. 
The number of granulocytes declined markedly in the sepsis group and platelets also 
declined significantly.
TAT and the pro-inflammatory cytokines TNF-, IL-1, IL-6, IL-12, the chemokine IL-8
and the anti-inflammatory cytokine IL-10 all increased in the sepsis group.
Soluble TCC, C-reactive protein, transforming growth factor 1, heart fatty acid binding 
protein and liver fatty acid binding protein were below detection limit.
4.5 Paper V
This paper documents the specific role of LPS versus other membrane components of 
meningococci in the evolvement of meningococcal sepsis. 
Of the cardiovascular parameters SVRI decreased only in response to NmLPS+, while kept 
stable or even increased in response to NmLPS-. There was also a decrease in MAP towards 
the end in response to NmLPS+ which was not seen with NmLPS-. Lactate, indicating 
hypoperfusion of the tissues, increased only in response to NmLPS+. MPAP and PVRI 
increased in response to NmLPS+ and NmLPS-, but the increase appeared earlier in response 
to NmLPS+. 
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The fluid requirement of the pigs receiving NmLPS+ was considerably higher than the 
requirement of the pigs receiving NmLPS-. However, even the latter group required 
significantly more fluid than the control group to keep the blood pressure, and the pigs 
receiving the lowest numbers of NmLPS+ had comparable need for fluid as the pigs 
receiving the highest numbers of NmLPS-. There was a substantial decrease of intravascular 
albumin due to capillary leakage in both groups receiving bacteria, but the decrease appeared 
more immediate in the NmLPS+ group. The mean final decrease of intravascular albumin 
was 40% in the NmLPS+ group and 30% in the NmLPS- group. Peak inspiratory pressure, 
reflecting increased stiffness of the lungs due to pulmonary edema, increased substantially 
only in the NmLPS+ group. Wet/dry ratio in the left lung and jejunum was higher with 
NmLPS+ than NmLPS- while wet/dry ratio of the right lung and the muscle was only 
increased in the NmLPS+ group compared to the control group. 
Hemoglobin increased temporarily in the NmLPS+ group, while a continuous increase 
towards the end was seen in the NmLPS- group. Granulocytes were virtually depleted from 
the circulation in the NmLPS+ group, but did not change in the NmLPS- group except for in 
the pig given the highest numbers of NmLPS- where a marked decrease appeared at the end 
of the experiment. Platelets decreased in both groups receiving bacteria.
TAT and PAI-1 increased in both groups receiving bacteria, but most in the NmLPS+ group.
All the inflammatory cytokines analyzed, i.e. TNF- 9-  9-6, IL-8, IL-10 and IL-12,  
increased substantially more in response to NmLPS+ than in response to NmLPS-. IL-8 was 
only increased in the NmLPS+ group. There was a dose-dependent increase of IL- 9-6
and IL-8. The pigs receiving the lowest numbers of NmLPS+ bacteria had comparable 
cytokine responses to the pigs receiving the highest numbers of NmLPS- bacteria.
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5 Discussion
The last decade has brought comprehensive new insight into the concept of pathogen 
associated molecular patterns (PAMPs), i.e. conserved microbial structures, and their 
interactions with the innate immune system (136). This great extension of our insight into 
such mechanisms was initiated by the discovery of Toll-like receptors as key players in the 
innate immunity and how the activation of TLRs by various PAMPs led to activation of 
leukocytes and other cells taking part in the inflammatory response (137). In turn, this has 
brought increased attention to the role of innate immunity mechanisms in inflammation in 
general and how the different parts of the innate immune system interact with each other as 
well as with the adaptive immune system (136). The failure of previous trials to show 
advantageous effects of blocking single inflammatory mediators in septic patients has also 
encouraged a broader perspective of the inflammatory response in sepsis (63,138-140). The 
primary achievement of this Thesis has been to gain new insight into details about the 
interaction between pathogen structures of meningococci and the immune system leading to 
inflammatory responses and development of the clinical state of sepsis on the one hand, but 
also being essential for the host defense against meningococcal disease on the other hand. 
A major focus of the studies has been how specific meningococcal pathogen structures are 
involved when the inflammatory networks are triggered and sepsis develops, and also the 
dose-dependency of such interactions. In most of the in vitro and in vivo models used in the 
studies we have taken advantage of previous investigations showing how the growth rate of 
meningococci and thus, the concentration of PAMPs being present,  determines the course of 
meningococcal disease after the bacteria have managed to invade from the nasopharyngeal 
mucosa into the blood (23-25,74).
5.1 Dose dependency of inflammatory mechanisms triggered by 
N. meningitidis 
  
The first paper, modeling different stages of meningococcal disease in vitro by adding 
increasing numbers of meningococci to serum, whole blood and transfected HEK293 cells,
demonstrates how the transition from a low-grade bacteremia to fulminant sepsis is 
associated with a parallel transition from a non-detectable inflammatory response to a 
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massive inflammatory state with high levels of pro-inflammatory mediators present. The 
experiments demonstrate how the inflammatory responses are differentiated with respect to 
the different mechanisms and triggering pathogenic structures involved. CD14 dependent 
TLR4 mediated signaling initiated by the binding of LPS was shown to be the most sensitive 
mechanism in our systems, provoking inflammatory responses in the whole blood system as 
well as in the transfected HEK293 cells at concentrations of meningococci from 103 – 104
bacteria/mL. This mechanism proved to be the dominant inflammatory mechanism up to 106
bacteria/mL. The threshold for appearance of complement dependent inflammation, mainly 
mediated by C5a, was 105 – 106 bacteria/mL, the concentrations being equal to the lower 
range seen in patients developing fulminant sepsis (23-25).  Signaling by TLR2 in the 
HEK293 cell system was not evident before the bacterial number reached the upper range 
seen in patients with fulminant sepsis, i.e. 107 bacteria/mL. While CD14 was a prerequisite 
for the activation of TLR4 at low to medium bacterial concentrations, our experiments 
demonstrated that with the bacterial numbers increasing up to the extremely high 
concentrations associated with fulminant sepsis, TLR4 can be activated independently of 
CD14. This indicates that the role of CD14 in meningococcal disease is primarily to enhance 
the ability of the immune system to respond to LPS in the initial phase of the disease, while 
TLR4 can readily be activated without the facilitating mechanism of CD14 when the amount 
of LPS becomes abundant. These findings are in line with previous findings by Sprong et.al. 
(141). Also, our experiments with HEK293 cells indicate that the facilitating effect of CD14 
in TLR2 mediated signaling by meningococci is limited, although some effect may be 
present according to our whole blood experiments with NmLPS-. CD14 may be more 
important in TLR2 mediated signaling by other pathogens, activating TLR2 at lower 
concentrations than meningococci. 
In the serum model in paper I increased TCC was not detected until the bacterial 
concentration was substantially increased to 107 bacteria/mL. The TCC detected in these 
experiments were in the soluble form in plasma. The experiments in paper 2 and other 
studies of SBA demonstrate clearly SBA to be apparent, i.e. efficient insertion of MAC into
the bacterial membrane occurs, at lower bacterial concentrations (142). Thus, complement 
activation with formation of the terminal C5b-9 complex appears to be well controlled and 
directed to the target bacterial membrane up to very high numbers of meningococci, at the 
level of 107 bacteria/mL. Beyond this level activation of complement seems to be 
exaggerated with a large amount of soluble TCC being formed in plasma. Our experiments 
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indicate that activation of complement is primarily directed towards killing meningococci but 
with limited systemic inflammatory effects as long as the bacterial concentration does not 
exceed the level seen in low to moderate grade meningococccemia. When the bacterial 
numbers are increased to the high levels seen in severe meningococcal sepsis a breakdown of 
complement homeostasis appears, similar to the breakdown of the homeostasis of other 
plasma cascade systems like the coagulation system (143). Together with an exaggerated 
TLR mediated inflammatory activation, overriding the regular signaling mechanisms like the 
CD14-dependency, such activation probably leads to a “point of no return” where the 
inflammatory response finally results in the patient succumbing. Targeting inhibition of 
upstream mechanisms in this response, like the initial TLR signaling and the activation of 
complement, could be a future approach in the treatment of sepsis (63).
5.2 The role of C2, C5, MBL and antibodies for bacterial survival and 
proliferation, phagocytosis and serum bactericidal activity
Although the interaction between the innate and adaptive immune systems has become a 
field of recent interest, our understanding of some mechanisms of such interactions also dates 
long time back in the history of science. Antibody dependent activation of the classical 
complement pathway is an excellent example of this, being described for the first time about 
100 years ago (144). Paper two describes novel insight into details of the role played by 
complement and antibodies in the defense against meningococci, which is of special interest 
since this pathogen is strikingly inclined to cause disease in individuals with certain 
complement deficiencies (112,145). These results were obtained by experiments using whole 
blood and serum from two individuals being genetically completely deficient of complement 
factor C2 and C5, respectively (133). The experiments demonstrated C2 as well as C5 to be 
critical for the killing of meningococci in whole blood, indicating that none of the defense 
mechanisms against meningococci in peripheral blood, phagocytosis and serum bactericidal 
activity could operate efficiently without these two factors. C2-dependency with no influence 
of MBL, as we found, implies that classical complement activation is the essential initiating 
step, in accordance with previously published results (146,147). However, a role of the lectin 
pathway by involvement of ficolins cannot be completely ruled out by these experiments 
since MBL-independent activation by ficolins might occur. These results do not exclude the 
56
alternative pathway to be involved, as indicated by the increased susceptibility of individuals 
with deficiencies of the alternative pathway like properdin and factor D to acquire 
meningococcal disease and the protective role of the alternative pathway inhibitory factor H 
binding to meningococci (112,148,149). Involvement of the alternative pathway probably 
occurs mainly through amplification of the complement cascade after initial activation by the 
classical pathway (150). C2 bypass mechanisms, as has been proposed to occur in certain 
instances (151), were not observed in our experiments even when the classical pathway 
activation was enforced by adding high concentrations of anti-meningococcal antibodies. 
C5-dependency indicates that this factor is not only needed to form the terminal lytic 
complex but also is a prerequisite for efficient phagocytosis of meningococci and oxidative 
burst to occur. This is in accordance with previous experiments where C5a was found to be 
critical for the up-regulation of CD11b and the formation of H2O2, being essential for these 
mechanisms (44,127,133), although an excess of C5a as can be formed in sepsis has also 
been shown to shut down the granulocyte function (44). However, in the present study we
could not verify C5a dependency in the OPA experiments with heterologous granulocytes. 
This was probably due to artificially up-regulation of CD11b during their preparation ex 
vivo, as demonstrated in a separate experiment. 
The results of this study also indicate that while a high level of antimeningococcal antibodies 
is necessary for serum bactericidi to occur, phagocytosis can occur even in the presence of 
low background antibody levels. It is reasonable to speculate that efficient serum bactericidal 
activity requires abundant insertion of lytic MAC complexes into the meningococcal 
membrane, particularly in encapsulated strains as we used in these experiments, which in 
turn requires high levels of specific antibodies. In contrast, even in the presence of 
background antibody levels sufficient classical complement activation seems to take place to 
give some opsonic coating of meningococci and adequate up-regulation of CD11b. These 
results suggest phagocytosis to be a primary defense mechanism against intruding 
meningococci in non-immunized individuals having low SBA, corresponding to an apparent 
protection against meningococcal disease in the absence of a sufficient antibody titer for 
SBA to occur in some individuals (49). The specificity of antimeningococcal antibodies 
probably also determines whether phagocytosis or bactericidal effects will be effective (47).
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The results also indicate an independent role of antibodies to initiate phagocytosis without 
activating complement, probably by the involvement of Fc-receptors, but only when the 
antibodies are present in large amounts as after immunization.  Our experiments do not 
indicate any role of MBL in the defense mechanisms against meningococci. However, we 
cannot exclude that involvement of MBL, as has been suggested by others (152,153), can be 
present under certain conditions like in the case of reduced sialylation of LPS, supposed to 
occur by phase switching after the meningococci breach the pharyngeal mucosa (154), since 
sialic acid is thought to hide MBL-binding targets on the bacterial surface (147,155,156).
5.3 The influence of erythrocyte CR1-binding of Gram-negative bacteria 
on phagocytosis and oxidative burst, and the handling of the bacteria 
in vivo
Phagocytosis and oxidative burst are normally studied with isolated populations of 
leukocytes, primarily granulocytes (157). In the third paper we utilized the whole blood 
model with the specific thrombin inhibitor lepirudin as anticoagulant to study the interaction 
of Gram-negative bacteria with erythrocytes and leukocytes.  N. meningitidis and E. coli 
opsonized with C3 and C4 split products bound rapidly to erythrocyte CR1 receptor. By this 
interaction with the erythrocytes phagocytosis by granulocytes and monocytes were 
impeded, as demonstrated by the increased phagocytosis and oxidative burst occurring when 
CR1 binding of the bacteria to erythrocytes was blocked. Thus, it appears that binding of 
these bacteria to erythrocytes protects against phagocytosis and oxidative burst by circulating 
leukocytes. These findings are in line with previous studies where binding of immune 
complexes to erythrocyte CR1 has been found to inhibit activation of granulocytes (158,159).  
Interestingly, in the first study of the immune adherence phenomenon with bacteria by 
Nelson from 1953 it was shown that  the phagocytosis of pneumococci by guinea pig 
macrophages increased in the presence of human erythrocytes (116). Subsequent studies 
have confirmed the particular importance of the mononuclear phagocyte system of the liver 
for the removal of circulating bacteria and apparently only a minor proportion of circulating 
bacteria are phagocytosed by circulating leukocytes (160-162). These findings are in line 
with a recently published study demonstrating a functional role of erythrocyte CR1 in 
clearance of pneumococci from the circulation by facilitating the transfer of pneumococci to 
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liver macrophages (118). Interestingly, the proportion of bacteria being associated with the 
erythrocyte fraction in the in vivo studies we performed using the porcine model of sepsis 
was substantially lower than we found in the in vitro experiments with human whole blood. 
Notably, the erythrocytes of pigs probably do not possess CR1 or similar receptors, as these 
are restricted to primates (163). Thus, the nature of bacterial binding to porcine erythrocytes 
is not clear. We speculate that the low proportion of bacteria bound to erythrocytes in the 
pigs could partly explain why a majority of the bacteria was removed from the circulation by 
the lungs and not by the liver. It appears that erythrocyte CR1 binding of complement
opsonized bacteria can serve as a mechanism to protect against systemic inflammation 
through directing the pathogenic agents particularly to the liver where they can be more 
safely deposited by the mononuclear phagocyte system with less systemic inflammatory 
responses. This implies a supplementary role of complement to its commonly regarded 
primary functions of mediating phagocytosis and serum bactericidal activity and can have 
implications for a potential use of complement inhibition as suggested as adjuvant therapy in 
sepsis (44,164)
The experiments performed with different complement inhibitors supply information about 
how different parts of the complement system are involved in mediating phagocytosis. 
Interestingly, we found that when activation of C3 was inhibited, the deposition of C4b on 
the surface of the bacteria not being inhibited was increased. This increase was probably due 
to more space for C4b deposition on the complement binding membrane structures of the 
bacteria and such C4b deposition probably explains why some binding of bacteria to 
erythrocytes was seen despite complement inhibition. As expected, inhibition of the C5a 
receptor did not affect opsonization of the bacteria, but significantly reduced phagocytosis. 
This is in accordance with the results of previous studies where C5a was found to be a key 
factor for up-regulation of CD11b/CD18 (CR3) being essential for phagocytosis in 
granulocytes (127,133,134).
This study also supply additional information about expected effects of complement 
inhibition in sepsis, suggested as a potential new therapeutic approach to attenuate the 
inflammatory response in such patients (44,164). By using a complement inhibitor acting 
early in the complement cascade, i.e. at the C3 level or previous steps, the bacterial 
opsonization would be decreased, leading to reduced bacterial binding to erythrocytes and 
consequently increased numbers of free bacteria in plasma. Decreased opsonization and
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decreased up-regulation of CR3 would also lead to reduced phagocytosis by peripheral 
leukocytes and probably also tissue macrophages, further increasing the number of free 
bacteria in plasma. Decreased phagocytosis may decrease those parts of the septic 
inflammatory response being related to granulocyte activation and oxidative burst, i.e. 
release of reactive oxygen metabolites and other products thought to be important in some of 
the pathophysiological changes of sepsis, particularly capillary leakage (33,159). However, 
increased concentrations of circulating pathogens, even if they are dead due to adequate 
antibiotic treatment, will probably also increase the exposure of PAMPs to the inflammatory 
system and consequently give disadvantageous increased inflammatory response. An 
alternative strategy is to inhibit complement at a later step like C5a, which implies that the 
bacteria will still be fully opsonizied and may bind to erythrocyte and leukocyte CR1, as well 
as leukocyte CR3. According to our results, although phagocytosis by granulocytes is 
inhibited, phagocytosis by monocytes and thus, probably also tissue macrophages, can still 
be relatively effective when C5a is inhibited.  Thus, inhibition of C5aR may be the most 
suitable approach when searching for a complement inhibitor to be used in sepsis.
5.4 The new porcine model of meningococcal sepsis   
An important object of this thesis has been to unite the in vitro and in vivo approach towards 
experimental studies of meningococcal sepsis. While in vitro studies are needed to 
investigate specific details, studies in vivo are necessary to prove effects on the whole 
organism which is of course of fundamental relevance to understand how meningococcal 
disease develops. A suitable in vivo model is also a necessity when new potential therapeutic 
principles are to be explored. Accordingly, we developed a new porcine model of 
meningococcal sepsis. Such a large animal model is superior to murine models in several 
aspects: Porcine and human cardiovascular physiology are relatively similar (165). The pig 
can be monitored with the same instruments as used for surveillance of patients and the large 
blood volume in pigs allows for a broad range of samples at several time points during the 
experiments. The fluid resuscitation used in this model was similar to that used in human 
septic patients. Furthermore, human and porcine LPS responsiveness are similar, in contrast 
to mice and rats which are relatively resistant if not presensitized to LPS (166,167). The 
model was designed to simulate the rapid and exponential growth of meningococci in 
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patients with fulminant meningococcal sepsis. No such animal model of meningococcal 
sepsis has been developed previously. 
Although compressed with regard to time, a broad spectrum of changes including 
cardiovascular parameters, vascular leakage, cytokine release, and changes in hematological 
and coagulation parameters paralleled those observed in patients. The study gained insight 
into the early events of the development of meningococcal shock. Leakage of plasma out of 
the vascular compartment was found to appear from an early stage when the bacterial 
concentrations in blood still were relatively low. As the bacterial concentration increased 
towards 105 – 106 bacteria/mL, which is comparable to what is found in patients with 
fulminant meningococcal sepsis, the capillary leakage became more profuse. However, as 
long as the intravascular volume deficit was sufficiently substituted by intravenously
administrated fluid, hypotension was avoided. When the peripheral resistance decreased 
during the final hour of the experiments, large volumes of administrated fluid were not 
sufficient to stabilize the circulation and neither was the heart able to compensate by 
increasing the cardiac output. Thus, hypotension apparently evolved as a result of decreased 
vascular resistance in combination with a relative compromised cardiac performance. 
The abrupt increase observed in pulmonary hypertension may be more pronounced than in 
humans with sepsis and is probably due to specific features of the porcine lung endothelial 
lining with particular abundance of macrophages (168,169).
Of the pro-inflammatory cytokines measured, TNF-)
	increase, followed by a
decline during the observation. Such a pattern of TNF- is also seen after bolus injections of 
LPS (166), and probably occurred due to a rapid down-regulation of this cytokine in 
response to the high bacterial load. Additionally, since we measured the amount of protein 
using ELISA assay, binding of TNF- to soluble receptors might cover detection epitopes 
and thereby interfere with the assay. The absolute increase in TNF-, being in the order of 
10 ng/mL, was in fact somewhat more pronounced than observed in patients with 
meningococcal sepsis commonly having concentrations of TNF- less than 1 ng/mL (29).
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to about the same level as seen in patients with such disease (29,170). The concentration of 
IL-6 was in the same range as seen in patients with meningococal sepsis (29), and the level 
of IL-8 in the septic pigs was in the lower range of that seen in patients with sepsis (28). The
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maximum level of the important anti-inflammatory cytokine IL-10 (171) was in the range of 
0.3 ng/mL, similar to the porcine E. coli sepsis model also developed by our group (172).
This is considerably lower than in patients with meningococcal sepsis at the time of 
admittance to hospital, normally having IL-10 concentrations in the range of 1-100 ng/mL 
(30,173). In vitro studies suggest that IL-10 is released with a slower kinetics than most of 
the pro-inflammatory cytokines reaching peak levels between 8 and 24 hours (174). Given 
the four hour time span of the experiments IL-10 was not up-regulated to the same extent as 
observed in patients with fulminant septicemia where the time from onset of the disease 
symptoms to hospital admission last median 12 hours and rarely <8 hours (19,30,173,175).
In this respect the new model is not reflecting the powerful anti-inflammatory response 
observed in patients with fulminant meningococcal septicemia (30,75,171,173,175). Taken 
together, our results and the previous in vitro and clinical studies indicate that IL-10 is in fact 
released slower than the pro-inflammatory cytokines although fast enough to reach high peak 
values within the time frame of admittance to hospital.
5.5 The inflammatory role of LPS and non-LPS molecules of 
N. meningitidis examined in vivo in the porcine model of 
meningococcal sepsis
The porcine model was applied to perform experiments documenting for the first time in a 
large animal model the specific role of LPS, for long time assumed to be the essential PAMP 
of meningococci, versus other meningococcal compounds in the development of sepsis. The 
results confirmed that N. meningitidis LPS is by far the most potent group of outer membrane 
molecules that trigger the innate immune system and subsequent inflammatory responses. 
However, it demonstrated that non-LPS molecules in meningococci are capable of inducing 
complex pathophysiological responses leading to marked organ dysfunction.
The most apparent LPS-specific circulatory difference was the divergent changes seen in 
peripheral resistance. Decreased SVRI, as appeared only in the NmLPS+ group, occurred 
despite the administration of norepinephrine, indicating LPS-induced decreased sensitivity to 
catecholamines as a causative factor of vasoplegia in septic shock (176,177). In contrast, 
PVRI increased to the same level in both sepsis groups, although significantly earlier in the 
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NmLPS+ group. This indicates that non-LPS components of meningococci also are 
important inducers of pulmonary vasoconstrictors, like thromboxane A2 and endothelin 
(178)
Capillary leakage, thought to be a major pathophysiological event in meningococcal sepsis 
(179), was in paper IV found to be an early event leading to hypovolemia. All indicators of 
capillary leakage used in the present model demonstrated LPS to be the most important, 
although not the sole molecule responsible for this event. Even in the NmLPS- group 
intravascular albumin decreased and there was a substantial dose-dependent need for extra 
fluid replacement. Also, a continuous hemoconcentration appeared in the NmLPS- group 
despite the high volumes of fluid infused, strongly supporting leakage of large plasma 
volumes out of the circulation. 
Regarding the leukopenia characteristically seen in fulminant meningococcal sepsis, caused 
by up-regulation of various adhesion molecules on endothelial cells and the leukocytes 
themselves (14), our results clearly show that LPS is the major molecule responsible for this
event. However, at high concentrations other molecules of meningococci may contribute to 
such up-regulations, as the pig receiving the highest number of NmLPS- bacteria also had 
marked decrease in the number of circulating granulocytes. 
DIC, being a characteristic phenomenon in severe sepsis, develops as a result of increased 
systemic coagulation due to up-regulation of tissue factor and decreased fibrinolytic capacity 
(36,37,39). By measuring TAT and PAI-1 both these aspects of changes in coagulation were 
studied. In addition, the consumption of platelets was also measured. The results emphasize 
LPS as the most important causative factor of hemostatic pathology, although other 
molecules may contribute to a lesser extent. 
LPS proved to exert a dominant influence on all cytokines measured, i.e. TNF-9- 9-6,
IL-8, IL-10 and IL-12. However, TNF-, IL-1, IL-6 and IL-10 also increased in the
NmLPS- group, but mostly in the pigs receiving the highest numbers of mutants. 
Interestingly, IL-8 was found to be the most LPS independent cytokine in our in vitro 
studies, but in the in vivo study IL-8 was the only cytokine being increased solely in the pigs 
receiving NmLPS+. This discrepancy does not relate to different species being studied, as 
other in vitro studies with porcine whole blood also have demonstrated LPS independency of 
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IL-8 (180). Rather, such discrepancy indicates substantial differences in the regulation of this 
cytokine in vitro and in vivo.
The concentrations of TNF-, IL-1 and IL-6 were comparable in the pigs receiving the 
highest numbers of NmLPS- and the lowest numbers of NmLPS+, indicating that wild type 
meningococci stimulate the pro-inflammatory cytokine secretion with about 10 to 20 fold 
higher potency than the mutant strain in vivo. Such difference in potency between the effect 
of meningococci with and without LPS corresponded well with our clinical observations of 
the pigs. In fact, this difference is markedly less than the difference we found in cytokine 
secretion when whole blood was incubated with NmLPS+ and NmLPS- in paper I, and also 
less than the difference in in vitro experiments performed by others (76-78). Thus, although 
the difference between LPS and other meningococcal structures in their capacity to induce 
cytokine secretion and inflammatory changes is clearly evident even in our in vivo model, it 
appears that the difference may be less pronounced in vivo than in various in vitro models. 
This emphasizes the role of the various organs in the inflammatory response, a field which 
have been scarcely studied so far.
The effects observed with the NmLPS- strain could not be explained by a modest 
concentration of LPS in this preparation. The strain is completely devoid of LPS (119) and 
the minimal LPS activity of the bacterial suspension used for infusion (2 EU/1010 bacteria), 
regarded as contamination from the growth medium, is far below the amount needed to 
induce any biological response. This is also in accordance with the fact that no LPS were 
detected in the blood at the end of the experiments in the NmLPS- group.
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6 Conclusions 
6.1 Bacterial load
The complexity of the inflammatory response to N. meningitidis is highly dependent on the 
bacterial load. At low to moderate bacterial concentrations in the blood CD14 dependent 
signaling via TLR4 is the sole pathway being activated. At higher concentrations of 
meningococci other inflammatory mechanisms including complement activation and CD14 
independent signaling via TLR4 and TLR2 become increasingly important.
6.2 Complement activation
Activation of complement is well balanced and directed towards killing meningococci by 
deposition of opsonic fragments and insertion of the C5b-9 lytic complex into the bacterial 
membrane as long as the concentration of meningococci does not exceed the levels seen in 
low to moderate grade meningococcal sepsis. When the bacterial numbers are increased to
the high levels seen in severe meningococcal sepsis, the inflammatory effects of complement 
activation become more pronounced and ultimately a breakdown of complement homeostasis 
appears.
6.3 Phagocytosis and serum bactericidi
Phagocytosis and serum bactericidal activity contribute collectively in the defense against 
intruding meningococci. Both mechanisms are dependent on complement activation by the 
classical pathway and probably also activation of C5. Phagocytosis occurred in the presence 
of low background levels of antibodies but increased after immunization. Serum bactericidal 
activity was dependent on the presence of antibodies in the serum.  
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6.4 Erythrocyte CR1 binding
Gram-negative bacteria opsonized with C3 and C4 complement factors bind to erythrocyte 
CR1 and this interaction with the erythrocytes decreases phagocytosis by granulocytes and 
monocytes and probably influence the handling of the bacteria in vivo.
6.5 In vivo model
The porcine model we established proved to be suitable to study a broad range of 
pathophysiological and immunological aspects of meningococcal sepsis. Characteristic 
pathophysiological changes occurred in relation to the release of large amounts of 
inflammatory cytokines. 
6.6 Pathophysiology
Capillary leakage was found to be an early event in the porcine model of meningococcal 
sepsis, increasing with increasing bacterial load. However, hypotension was avoided with 
sufficient volume replacement as long as there were no alterations in the vascular resistance. 
Circulatory failure with hypotension evolved as a result of decreased vascular resistance in 
combination with a relative compromised cardiac performance.
6.7 LPS
LPS was demonstrated to be the primary molecule of N. meningitidis to induce inflammation 
in vitro and in vivo. However, the difference between LPS and non-LPS membrane structures 
appeared to be more pronounced in vitro than in vivo with a difference in potency of about 
3 log10 in vitro and about 1 log10 in vivo.
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7 Future perspectives
Despite increasingly detailed insight into the inflammatory response to N. meningitidis, this 
has not led to advances in the treatment of meningococcal sepsis. Accordingly, more 
research is needed to obtain a better general understanding of the underlying inflammatory 
mechanisms leading to the pathophysiologic changes in this disease. In order to search for 
potential new therapeutic approaches, one should in our opinion look for inhibitors acting on 
a broad range of the inflammatory mediators being induced in sepsis, as previous studies 
targeting single mediators have not proven successful. This is in accordance to the present 
view of the septic inflammatory response involving a broad range of particularly the innate 
immune system being triggered by pattern recognition mechanisms. 
In vitro studies are normally performed with cultured cell lines, isolated leukocytes, whole 
blood or serum. Further investigations on how the whole organism and individual organs 
contribute to the septic inflammatory state are warranted.  We will perform such 
investigations based on material from the porcine model.  In addition we intend to study post 
mortally the aggregation of LPS and meningococci in various organs from humans having 
died from meningococcal sepsis, and the corresponding organ specific inflammatory 
response.  We have also started further investigations to clarify the interaction between 
complement and antibodies in phagocytosis and serum bactericidal activity, and the role of 
C5a in the regulation of phagocytosis and oxidative burst by use of serum and whole blood 
from Norwegian individuals recently detected to be C5 deficient. 
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3Abstract
Erythrocytes play a pivotal role in transport of opsonised agents via complement receptor 1 
(CR1), but how Gram-negative bacteria interact with erythrocytes, and the implications 
thereof, has not previously been studied. We therefore investigated the interaction of 
Escherichia coli and Neisseria meningitidis with erythrocytes and how this interaction 
affected phagocytosis and oxidative burst in human whole blood. Bacteria free in plasma, 
erythrocyte-bound or phagocytosed were quantified using flow cytometry. Most bacteria 
(80%) bound immediately to erythrocytes. The binding gradually declined with time, with a 
parallel increase in phagocytosis. C3 inhibition reduced erythrocyte binding and bacterial 
opsonization. C5a receptor blockade abolished phagocytosis, but binding of bacteria to 
erythrocytes was not influenced. CR1-blocking dose-dependently inhibited erythrocyte 
bacterial binding to nil, with subsequent increased phagocytosis and oxidative burst. Similar 
results were obtained with an LPS-deficient N. meningitidis mutant. In vivo porcine 
experiments demonstrated limited association of bacteria with erythrocytes, consistent with 
absence of erythrocyte CR1-like receptors in non-primates, and the bacteria were mainly
deposited in the lungs. In conclusion, binding of Gram-negative bacteria to human erythrocyte
CR1 decrease phagocytosis and oxidative burst by leukocytes in whole blood and may direct 
the bacteria to more safe deposition in the liver and spleen. 
4Introduction
Erythrocytes are generally viewed as simple hemoglobin carriers involved in oxygen transport 
in humans. However, the first observation that erythrocytes may bind microorganisms and 
play a role in the pathogenesis of bloodstream infections was in 1930 using serum-opsonized 
trypanosomes.1 Nelson later demonstrated that opsonized particles and Gram-positive 
pneumococci bind to erythrocytes in a complement dependent manner.2 Subsequently, the 
erythrocyte complement receptor 1 (CR1) was identified as the high-affinity binding site of 
C3b with lower affinity binding to iC3b, C4b,3 C1q and mannan-binding lectin (MBL)4
linking complement-coated bacteria to erythrocytes.5 A number of later studies have examined 
the binding of immune complexes (IC) to erythrocyte CR1 and the involvement in IC 
clearance.5
CR1 is a large transmembrane glycoprotein consisting of several homologous motifs.5 It is 
expressed in varying numbers, from approximately 100-1000 per human erythrocyte5 and 
occurs in clusters on the erythrocyte membrane after ligation.6,7 CR1 is also found on human 
monocytes, granulocytes8 and B-lymphocytes.5 Immune complexes opsonized with C3b and 
C4b bind to erythrocyte CR1 and can then be cleared from the circulation and destroyed in the 
liver and spleen.9,10 Another interesting feature of CR1 is its ability to inhibit complement 
activation by function as a co-factor for factor I which cleaves C3b and C4b to inactive 
forms.11 Through the binding of C3b and C4b, CR1 also accelerates the decay of the 
alternative12 and classical pathway C3 convertases.11 However, erythrocyte binding of Gram-
negative bacteria and the implications of such binding for the fate of the bacteria in human 
whole blood has not, to our knowledge, been previously studied.
5Escherichia coli (E. coli) and Neisseria meningitidis (N. meningitidis) are important Gram-
negative pathogens causing sepsis.13,14 The organisms activate complex inflammatory 
mechanisms, involving the innate as well as the adaptive immune systems.15 Activation of 
complement is a key feature, being important for the defense mechanisms 
opsonophagocytosis16 and serum bactericidal activity to occur. Complement activation also 
have potent inflammatory effects through the release of anaphylatoxins including C5a in 
sepsis17 and excessive activation of complement  in meningococcal disease is related to 
disease severity.18
In this study we investigated the interaction of E. coli and N. meningitidis with erythrocytes 
and how such interaction influence phagocytosis in a human whole blood model. The specific 
thrombin inhibitor lepirudin was used as anticoagulant since it does not affect complement 
activation in contrast to calcium-binding anticoagulants and heparin.16 Experiments were also 
performed in vivo by intravenous administration of fluorochrome-labeled bacteria in a porcine 
model of sepsis, since porcine erythrocytes lack CR1. The data shed new light over the 
interaction of Gram-negative bacteria with the various blood cells and indicate that erythrocyte 
binding protects the bacteria against phagocytosis and reduces leukocyte oxidative burst in 
human whole blood.
6Materials and methods
Reagents
All equipment including polypropylene tubes from Nalgene NUNC (Roskilde, Denmark), and 
tips used in the whole blood experiments was endotoxin-free. Phosphate-buffered saline (PBS)
with or without Ca2+ and Mg2+ were obtained from Life Technologies (Paisley, UK).
Lepirudin (Refludan) was obtained from Hoechst (Frankfurt am Main, Germany). Protein G 
Spin Kit columns (0.2 mL) for antibody purification were obtained from Thermo Fisher
Scientific (Pierce, Rockford, IL). The Burst test and Phago test kits were both obtained from 
ORPEGEN Pharma (Heidelberg, Germany). Alexa 488, the BacLight green kit for direct 
fluorescent staining of unlabeled bacteria and dimethylsulphoxide (DMSO) were obtained 
from Invitrogen Molecular Probes (Eugene, OR). Ethylenediaminetetraacetic acid (EDTA) 
and bovine serum albumin were obtained from Sigma-Aldrich (St. Louis, MO).
Antibodies and inhibitors
The anti-CR1 blocking mAb (clone 3D9) inhibits the binding of CR1 to C3b/C4b and has 
been extensively characterized previously.19 The mAb 3D9 was purified from 50 L sterile 
ascites fluid containing approximately 1 mg/mL mAb using protein G columns. The 
concentration of the purified 3D9 IgG1 antibody in the eluate (0.46 mg/mL) was analyzed at
280 nm using a SmartSpecTMPlus Spectrophotometer from Bio-Rad (Hercules, CA). An 
isotype matched control IgG1 mAb (clone BH1) was purchased from Diatec (Oslo, Norway).
Antibodies were tested for LPS contamination using the chromogenic LAL-assay QCL-1000 
from BioWhittaker (Walkersville, MD). If necessary, LPS was removed from the mAbs using 
7END-X from Cape Cod (East Falmouth, MA) to obtain final LPS concentrations in the low 
pg/mL range. Compstatin is a 13 aminoacid cyclic peptide which binds to and inhibits 
cleavage of C3. We used the compstatin analogue Ac-I[CV(1MeW)QDWGAHRC]T-NH2, 
which is 264 times more active than the parent peptide I[CVVQDWGH HRC]T-NH2. Both 
compstatin and a control peptide IAVVQ DWGHHRAT-NH2 were synthesised as previously 
described.20 The cyclic hexapeptide AcF[OPdChaWR], a C5a receptor antagonist (C5aRa),
was synthesized as previously described.21 The murine anti-human mAbs anti-C2 and anti-
factor D including the isotype-matched control mAb G3-519 has been described in detail 
previously.22,23
Bacterial preparations
E. coli strain LE392 (ATCC 33572) was obtained from American Type Culture Collection 
(Manassas, VA). E. coli was grown overnight on a Lactose dish and 5-10 colonies were 
transferred to LB-medium (1% Tryptone, 0.5% (w/v) yeast extract, 1% (v/v) NaCl) from
Becton Dickinson (Sparks, MD) and grown overnight. The bacteria were harvested and 
washed once with Dulbeccos PBS without Ca2+ and Mg2+ using centrifugation (3220g, 10
minutes, 4°C). Bacteria were aliquoted, heat inactivated for 1 hour at 60°C and stored at
-80°C. A frozen ampoule was thawed at ambient temperature and washed six times with PBS 
(3220g, 10 minutes, 4°C) to remove extracellular LPS. Bacteria intended for Alexa-staining 
were removed and the rest were washed additional three times. Bacteria were stained 5 
minutes with SytoBC from Invitrogen Molecular Probes. Thereafter, bacteria were counted in 
Truecount tubes (Becton-Dickinson) using a FACScalibur or a LSRII flowcytometer (Becton-
Dickinson). The heat-inactivated E. coli bacteria were stored in PBS at +4oC for up to two
8months. The LPS concentration in the supernatant of the bacterial preparation was unchanged 
during the storage period.
For use in the phagocytosis assay, heat-inactivated E. coli (6 x 109) or N. meningitidis were 
washed six times as described above and the supernatant discarded.23 Thereafter, NaHCO3 
(0.2 M, 600 µL, pH 8.35), sterile filtered and heat inactivated (1 hour, 60°C) was added 
together with 6 µL Alexa FLUOR® 488 carboxylic acid, succinimidyl ester (10 mg/mL) in 
DMSO. The tube was packed in tinfoil and rotated for 1 hour at ambient temperature. Bacteria 
were washed 3 times (8000g, 5 minutes), resuspended in PBS and counted as described above.
Heat-inactivated wild-type N. meningitidis 44/76 (also named H44/76) was obtained from the 
National Institute of Public Health (Oslo, Norway). This international reference strain is 
characterized as B:14:P1.7,16:L3,7,9 and was originally isolated from a patient with invasive 
meningococcal disease.24 The N. meningitidis 44/76 lpxA-mutant strain which completely 
lacks LPS in the outer membrane was created by L. Steeghs and P. van der Ley, National 
Institute of Public Health and Environment, the Netherlands,25 and donated to the National 
Institute of Public Health, Oslo, for research purposes. Both strains are encapsulated. Staining 
of these bacteria was performed as staining of E. coli.
Human whole blood sepsis model
The whole blood model has been described in detail previously.16 Briefly, samples were drawn 
from healthy donors into 4.5 mL NUNC tubes containing 50 g lepirudin/mL blood. The 
study was approved by the Regional ethics committee. Separate tubes with complement 
inhibitors or PBS controls were prepared, the blood was added immediately after sampling and 
9tubes were preincubated 4 minutes at 37C. Thereafter, PBS (control) or Alexa-stained or 
unstained bacteria was added and samples were further incubated at 37C. Inhibitor 
concentrations used: anti-C2 (71 µg/mL), anti-factor D (36 µg/mL), control mAb G3-519 (107 
µg/mL), compstatin (25 µM), the control peptide and C5aRa (both 10 µg/mL), and EDTA (10 
mM).
Flow cytometry of erythrocytes carrying bacteria and free bacteria in plasma
Whole blood incubated with inhibitors and Alexa-stained E. coli or N. meningitidis was fixed 
with 0.25% (v/v) paraformaldehyde for 4 minutes (37C). Samples were diluted 1:320 with 
PBS to avoid coincidences with erythrocytes not carrying bacteria and counted using 
Truecount tubes. Whole blood added 10 mM EDTA served as a control for coincidences. 
Samples were run on a FACSCalibur or LSRII flowcytometer (Becton Dickinson) with FSC 
and SCC in a log mode and threshold on the green channel. Gates were set around the beads, 
the erythrocytes and the free bacteria and calculations were made. The erythrocyte population 
was verified in control experiments using anti-Glycophorin A (Dako, Glostrup, Denmark). To 
verify that the bacteria/erythrocyte-conjugates did not appear because of PFA we performed 
control experiments without PFA and similar results were obtained.
Analysis of complement activation
Complement activation was analyzed as the terminal complement complex (TCC) using 
ELISA as previously described.26 Results are given as arbitrary units (AU/mL).
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Flow cytometry of bacterial opsonization
Lepirudin plasma was obtained after centrifugation at +4oC (3220g, 15 minutes). Plasma was 
preincubated 4 minutes with PBS or the indicated inhibitors at 37oC in NUNC tubes. 
Unopsonized E. coli, N. meningitidis or PBS was added and the incubation continued for 10 
minutes at 37oC. Bacteria were washed twice (3220g, 15 minutes, +4oC) and resuspended in 
PBS containing 0.1% (w/v) BSA. C1q, C3 and C4 opsonization was analyzed using rabbit 
anti-human C1q, FITC-conjugated rabbit anti-human C3c (F0201) and rabbit anti-human C4c 
mAbs, respectively. FITC-conjugated rabbit anti-mouse Ig was used as control. All antibodies 
were from Dako. Results are expressed as median fluorescence intensity (MFI). 
Phagocytosis assay
Whole blood incubated with inhibitors and Alexa-stained E. coli or N. meningitidis was 
processed according to kit instructions and phagocytosis of bacteria was analyzed in the 
presence of quenching solution. The assay in the absence of quenching solution reflects both 
phagocytosis and extracellular binding of the stained bacteria to leukocytes. Samples were run 
on a LSRII flowcytometer (Becton Dickinson) with FSC and SCC in a linear mode and 
threshold on FSC and data expressed as MFI.
Microscopy
Human whole blood was supplemented with PBS containing Alexa-stained E. coli or N. 
meningitidis (72 x 106/mL final concentration) and incubated 10 minutes at 37oC. Whole 
blood smears were made and immediately air dried. As a control, a portion of the whole blood 
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was diluted with PBS and examined as wet preparation by fluorescence microscopy. The 
smears were stored in the dark and examined using either the transmitted light observation 
microscopy or the reflected fluorescence procedure using appropriate filters for FITC and 
Alexa. 
Oxidative burst
Whole blood preincubated with inhibitors and E. coli was processed according to kit 
instructions as previously described.16 Samples were run on a LSRII flowcytometer (Becton 
Dickinson) with FSC and SCC in a linear mode and threshold on FSC. Results were expressed 
as MFI.
In vivo model of sepsis in pigs
Pigs (Sus scrofa domesticus) were anesthesized and treated surgically as previously
described.27,28 Two pigs received heat-inactivated Alexa-labeled E. coli and two pigs received 
Alexa-labeled N. meningitidis intravenously. A low dose of bacteria, 5.7 x 1010 in total were 
infused intravenously during the first 120 minutes through a central venous catheter (CVC). 
The initial dose was 4.5 x 108 bacteria/hour and the infusion rate was doubled every 30 
minutes up to 120 minutes. After 120 minutes, a bolus containing 9.2 x 1010 bacteria was 
injected during approximately 1 minute. Blood samples for cytospin preparations, qPCR of 
bacteria in whole blood, plasma, buffy coat and erythrocyte fractions, blood gas analysis, 
routine hematology and flow cytometry were collected from the pigs at the times indicated. 
Samples for qPCR were aliquoted and stored at -70°C. Haematological parameters including 
leukocyte differential count were analyzed in EDTA tubes on a CELL-DYN 4000 from Abbot 
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Diagnostics (Abbot Park, IL) as previously described.27 The pigs were treated with 
noradrenalin, fluid and sildenafilcitrate to prevent pulmonary hypertension. The experiments 
were performed in adherence to the Norwegian laboratory animal regulations and the study
was approved by the University Animal Care Committee.
qPCR for bacterial DNA in whole blood
Lepirudin anticoagulated whole blood was centrifuged (145g, 15 minutes at +4oC) without 
braking. Thereafter, the plasma, buffy coat and red cell fractions were collected and stored at 
-80oC. DNA from whole blood, plasma, buffy coat and red cell fractions were isolated on a 
MagNA Pure LC instrument (Roche Applied Science, Mannheim, Germany) according to the 
manufacturer’s instruction using a MagNA Pure LC DNA Isolation Kit I (Roche). Genomic 
DNA from E. coli O157, strain EDL 933 (Institute for Reference Materials and Measurements, 
Geel, Belgium) was diluted with water, quantified by optical density measurement and used as 
a standard. The standard was diluted 10-fold with whole blood anti-coagulated with lepirudin 
(108 to 103 E. coli DNA copies/mL), total DNA was isolated from 200 µL of each dilution and 
5 µL DNA extract was used for qPCR. The negative control was whole blood added sterile 
PBS and the positive control was DNA extracted from lepirudin anticoagulated whole blood 
mixed with DNA from E. coli strain B from Sigma-Aldrich. Quantification of E. coli DNA
was performed as previously described using qPCR on a ABI 7500 instrument (Applied 
Biosystems, Warrington, UK).29 Quantification of N. meningitidis DNA was also performed 
with qPCR (LightCycler; Roche Diagnostics, Basel, Switzerland), as previously described.30
The lower detection limit of the analysis for E. coli and N. meningitidis DNA were 1 x 104 and 
1x103 DNA copies/mL, respectively.
13
Statistics
Results were analyzed using SigmaStat version 3.5 (SPSS Science Software Gmbh, Erkrath,
Germany). Data were analyzed using one-way repeated measurements ANOVA followed by 
Holm-Sidak post test analysis using the bacteria plus PBS as control group. Significance was 
assigned where P< 0.05*.
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Results
Initial erythrocyte binding and phagocytosis of E. coli and N. meningitidis in human whole 
blood. The majority of the E. coli bacteria added to human whole blood were bound to 
erythrocytes after 10 minutes incubation (Figure 1A). Dose-response experiments showed a 
linear relationship between the concentrations of E. coli and the number of free bacteria in 
plasma and bacteria bound to erythrocytes (Figure 1A). Similar results were obtained for N. 
meningitidis (data not shown). A non-linear relationship between the phagocytosis of E. coli 
bacteria and the added bacteria concentration was found (Figure 1B). Finally, a linear 
relationship between E. coli concentration and complement activation in plasma, measured as 
TCC, was also found (Figure 1C). Control experiments confirmed that Alexa-labeled and 
unlabeled bacteria activated complement to the same extent (data not shown).
Fluorescence microscopy of smears from the blood confirmed that the E. coli bacteria initially 
bound to erythrocytes (Figure 1D), which was also the case for N. meningitidis (Suppl. Figure 
1A). Some phagocytosed bacteria were observed (Figure 1E) and occasionally, free bacteria 
were seen in plasma (Figure 1F). Similar findings were obtained using unlabeled bacteria and 
fluorescence microscopy after staining with fluorochrom-labeled anti-N. meningitidis or anti-
E. coli or BacLight (data not shown), indicating that Alexa-labeling of the bacteria did not 
influence the binding to erythrocytes. Furthermore, when microscopy was performed on 
diluted whole blood in wet fluid preparations, the bacteria were mainly found on erythrocytes, 
moving with the bacteria bound to their surface. Collectively, these data show that the 
majority of E. coli and N. meningitidis bacteria initially bound to erythrocytes when incubated 
in human whole blood. 
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Effect of complement inhibitors on the binding of bacteria to erythrocytes and on 
phagocytosis. The effect of complement inhibitors on the binding of E. coli and N.
meningitidis bacteria to erythrocytes was then examined. Approximately 80% of E. coli
(Figure 2A,B) and at least 90% of N. meningitidis (suppl. Figure 2A,B) initially bound to 
erythrocytes. Complement inhibition by mAbs blocking factor D and C2 significantly reduced 
the binding of E. coli and N. meningitidis to erythrocytes and simultaneously increased the 
number of free bacteria in plasma (Figure 2A,B and Suppl. Figure 2A,B). Complement 
inhibition completely blocked phagocytosis (p<0.05) by granulocytes and monocytes after 10 
minutes (Figure 2C,D). In comparison, an isotype control mAb had no effect. As expected, a 
C5aRa and a control peptide had no effect on the binding of the bacteria to erythrocytes. 
However, the C5aRa completely blocked phagocytosis by granulocytes and partially by 
monocytes after 10 minutes incubation (p<0.05). EDTA, blocking both complement- and cell-
activation, almost completely inhibited both the binding of bacteria to erythrocytes, leaving 
them in plasma (Figure 2A,B and Suppl. Figure 2A,B) and efficiently blocked the 
phagocytosis (Figure 2C,D and Suppl. Figure 2C,D). As a control, bacteria were added in PBS 
buffer in the absence of blood to check the bacterial number added (Figure 2A and Suppl. 
Figure 2A). 
Time course study on the effect of complement inhibitors on E. coli binding to erythrocytes 
and on granulocyte phagocytosis. The number of free E. coli bacteria in plasma was low at all 
time points, except in the presence of EDTA (Figure 3A). The binding of E. coli to 
erythrocytes was time-dependent and slowly decreased with time (Figure 3B). Complement 
inhibition using the C3 convertase inhibitor compstatin significantly decreased the binding to 
erythrocytes. The number of phagocytosed bacteria by granulocytes increased with time in the 
absence of inhibitor (Figure 3C). The data indicate that the complement-dependent binding of 
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bacteria to erythrocytes in vitro last several hours and the phagocytosis increases when the 
bacteria are released from the erythrocytes. However, neither compstatin nor EDTA 
completely inhibited phagocytosis after 60 and 120 minutes, indicating that the complement-
independent phagocytosis of E. coli increased with time. 
Effect of complement inhibitors on bacterial C3 and C4 opsonization. The effect of 
complement inhibitors compstatin and C5aRa on the C3 and C4 opsonization on E. coli and N.
meningitidis bacteria were then examined in lepirudin plasma using flow cytometry (Figure 4). 
Compstatin efficiently reduced C3 opsonization on both E. coli and N. meningitidis (Figure 
4A,C), whereas the C4 opsonization increased (Figure 4B,D). Notably, LPS had no effect on 
binding or inhibition of the opsonins since wild-type N. meningitidis and the LPS-deficient 
mutant behaved identical (Figure 4C,D). As expected, the C5aRa and its corresponding 
control peptide had no effect on bacterial opsonization. The calcium chelator EDTA 
efficiently blocked both C3 and C4 opsonization as expected, since it efficiently inhibits all 
complement activation pathways. C1q opsonization was very low and was not different from 
the MFI in the gamma control mAb (data not shown). 
Effect of the anti-CR1 blocking mAb 3D9 on the binding of E. coli to erythrocytes, on 
phagocytosis and on oxidative burst. The anti-CR1 blocking mAb 3D9 dose-dependently 
increased the number of free E. coli in plasma (Figure 5A) and simultaneously efficiently 
blocked E. coli binding to erythrocytes (Figure 5B). Interestingly, the anti-CR1 also 
effectively increased the granulocyte phagocytosis of the bacteria (Figure 5C). Similar 
findings were obtained for monocyte phagocytosis (data not shown). This finding suggests 
that the binding of bacteria to erythrocytes reduce leukocyte phagocytosis by reducing the 
number of bacteria available to leukocyte recognition. Microscopy of whole blood smears also 
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indicated that bacteria alone and not bacteria bound to erythrocytes were phagocytosed by 
leukocytes. 
The effect of anti-CR1 on E. coli-induced oxidative burst was then examined (Figure 5D). The 
anti-CR1 blocking mAb significantly increased (p<0.05) E. coli-induced oxidative burst in 
granulocytes. In comparison, a control mAb had no effect. The data indicate that blocking of 
bacterial binding to erythrocyte CR1 significantly increase phagocytosis and oxidative burst in 
leukocytes, implying that bacterial binding to erythrocytes protects against leukocyte oxidative 
burst in whole blood.
Effect of anti-CR1 mAb 3D9 on the binding to erythrocytes of N. meningitidis with and 
without LPS. To examine whether LPS was involved in the binding of bacteria to erythrocyte 
CR1, we examined the effect of the CR1 blocking mAb 3D9 on the binding of E. coli, wild-
type 44/76 N. meningitidis with LPS and the LPS-deficient 44/76lpxA-mutant to erythrocytes. 
All three bacteria efficiently and similarly bound to erythrocytes after 10 minutes incubation 
and the anti-CR1 blocking mAb 3D9 inhibited this binding completely (Figure 6). In 
comparison, an isotype control mAb had no effect. The calcium chelator EDTA also 
completely blocked the binding of all three bacteria to erythrocytes. As a control we also 
added the same concentration of all three bacteria to PBS buffer only, in the absence of whole 
blood (right columns), and the same concentration of bacteria was found as in the whole blood 
samples. The binding of N. meningitidis 44/76lpxA-mutant to erythrocyte CR1 clearly shows 
that this binding is LPS-independent.
In vivo experiments with Alexa-stained E. coli and N. meningitidis 44/76 in a porcine 
model of sepsis. Finally we wanted to obtain information about erythrocyte binding and the 
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fate of Gram-negative bacteria in vivo by the porcine model of Gram-negative sepsis, since pig 
erythrocytes lack CR1. The peak concentrations of E. coli and N. meningitidis were 6 x 107
and 2 x 105 bacteria/mL whole blood, respectively (Fig. 7A,B). The number of bacteria in the 
erythrocyte fraction, in plasma or in the buffy coat were then analyzed using qPCR of bacterial 
genome and the percentage in each fraction calculated (Figure 7C,D). The percentage of E. 
coli bacteria in the erythrocyte fraction was only 24% approx. five minutes after the bolus 
injection and decreased to 14% 55 minutes later (Figure 7C). During the same time period, the 
percentage of E. coli in plasma decreased from 42% to 30% and increased from 34% to 56% 
in the buffy coat fraction. In comparison, only 6% of N. meningitidis was in the erythrocyte 
fraction shortly after the bolus injection (Fig. 7D), indicating that pig erythrocytes, in contrast
to humans, hardly bind Gram-negative bacteria. Notably, immunofluorescence histology of 
lungs, spleen and liver of the pigs after 4 hours showed that the Alexa-stained bacteria was 
mainly located in the lungs and not in the liver and spleen (Figure S3).
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Discussion
The present study shows that erythrocytes rapidly bind the Gram-negative bacteria E. coli and 
N. meningitidis in human whole blood. This binding is complement-dependent, LPS-
independent and occurs through CR1. Blocking CR1 led to release of bacteria to plasma with 
enhanced phagocytosis and subsequent oxidative burst by leukocytes. The data thus provides 
new insights into important mechanisms involved in the pathophysiology of Gram-negative 
sepsis in humans, suggesting that erythrocyte binding of the bacteria protects against 
intravascular phagocytosis and, thus, attenuate systemic inflammation including oxidative 
burst. 
Since human erythrocytes express complement receptor CR1 and leukocytes express CR1 and 
CR3,5 we expected that both cell types would bind complement opsonized bacteria. The 
finding that approximately 80-90% of the Gram-negative bacteria initially binds to 
erythrocytes is per se most likely due to the approx. 400-1500 fold higher concentration of 
erythrocytes compared to leukocytes in human whole blood. In addition, erythrocyte CR1 may 
bind bacteria with a higher avidity than leukocyte CR1 as shown for the binding of IC.31 The 
reported ligands for human CR1 are C3b, iC3b, C4b, MBL and C1q.5 In this study, C3 and 
C4, but not C1q (data not shown) was detected on the bacterial surfaces. Complement factors 
seem to be the most important opsonins involved in the binding of Gram-negative bacteria to 
erythrocytes since inhibitors of complement activation at the level of C3 significantly reduced 
this binding. The increased C4 opsonization found after incubation with the C3 inhibitor 
compstatin probably occurred due to increased space for C4 deposition on the bacterial surface 
when the C3 deposition was reduced. Such C4b deposition probably explains why some 
binding of bacteria to erythrocytes was still seen when complement was inhibited. In 
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comparison, EDTA abolished both C3 and C4 opsonization with almost completely absent 
binding of bacteria to erythrocytes as a result. The anti-CR1 mAb 3D9, which specifically 
inhibits the binding of C3b/C4b to CR1,19,32 also completely blocked the binding to 
erythrocytes. This further indicates that C3b and C4b are the most important opsonins in the 
binding of bacteria to erythrocytes and that this binding occurs solely by binding to CR1. As 
expected, the C5aRa had no effect on the binding to erythrocytes, but significantly inhibited 
phagocytosis.16 The almost linear reduction in bacteria bound to erythrocytes with time 
indicates that the initial rate of bacterial release from erythrocytes is relatively constant. The 
release process is most probably due to a time-dependent change in the number of C3b 
molecules, converted by factor I to the less affinity CR1 ligand iC3b, on the bacterial 
surface.33,34,35 In addition, increasing phagocytosis of bacteria by leukocytes reduce the 
number of bacteria available for binding to erythrocytes.
The binding of bacteria to erythrocyte CR1 was LPS-independent since the N. meningitidis
LPS deficient mutant bound as efficiently to the erythrocytes and was as efficiently released 
when CR1 was blocked as the wild-type strain. Both the wild-type and the LPS-deficient N. 
meningitidis mutant used in this study are encapsulated, but the opsonization probably also 
occurs under the capsule surface. This is in line with the observation that the opacity protein in 
the subcapsular outer membrane and other neisseria structures binds C3b and C4b.36 The 
observation that both LPS-containing and LPS-deficient Gram-negative bacteria initially bind 
to erythrocyte CR1 further indicates that other bacterial structures than LPS bind C3b and 
C4b.
The rapid binding of bacteria to erythrocytes may affect and delay the reactions of peripheral 
leukocytes to bacteria in the circulation, as indicated by our finding that blocking CR1 
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increased the E. coli-induced phagocytosis and oxidative burst in monocytes and neutrophils. 
This is in accordance  with previous studies using immune complexes showing that binding of 
immune complexes to erythrocyte CR1 inhibited IC mediated activation of neutrophils.37,38
Interestingly, in the first study of the immune adherence phenomenon with bacteria by Nelson 
from 1953 it was shown that the phagocytosis of pneumococci by guinea pig macrophages 
increased in the presence of human erythrocytes.2 Subsequent studies have confirmed the 
particular importance of the mononuclear phagocyte system of the liver and spleen for the 
removal of circulating IC and bacteria and apparently only a minor proportion of bacteria in  
the blood are phagocytosed by circulating leukocytes.39,40,41, These findings are in line with a 
recently published study demonstrating a functional role of erythrocyte CR1 in clearance of 
pneumococci from the circulation by facilitating the transfer of pneumococci to liver 
macrophages.42
Interestingly, the proportion of bacteria being associated with the erythrocyte fraction in the in 
vivo studies using the porcine model of sepsis was substantially lower than we found in the in 
vitro experiments with human whole blood. Notably, the erythrocytes of pigs do not express 
human CR1 or similar receptors, as these are restricted to primates.5 We speculate that the low 
proportion of bacteria bound to erythrocytes in the pigs, could explain why a majority of the 
bacteria was removed from the circulation by the lungs and not by the liver.29 In addition, 
capillaries in porcine lungs are lined with macrophages probably involved in the removal of 
bacteria from the circulation. It appears that binding of complement opsonized bacteria to 
erythrocyte CR1 can serve as a mechanism in humans to protect against systemic 
inflammation by directing the pathogenic agents particularly to the liver and spleen where they 
can be more safely deposited by the mononuclear phagocyte system with less systemic 
inflammatory responses. This implies a supplementary role of complement to its commonly 
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regarded primary functions of mediating phagocytosis and serum bactericidal activity, and 
might have implications for a potential use of complement inhibition as suggested as adjuvant 
therapy in sepsis.43
The effects of specific complement inhibitors may have several possible implications on the 
bacterial binding to erythrocytes. By using a complement inhibitor acting early in the 
complement cascade, i.e. at the C3 level or previous steps, the bacterial opsonization would be 
decreased, leading to reduced bacterial binding to erythrocytes and consequently increased 
numbers of free bacteria in plasma as shown in this study. Decreased opsonization and 
decreased up-regulation of CR323 would also lead to reduced phagocytosis by peripheral 
leukocytes and probably also tissue macrophages, further increasing the number of free 
bacteria in plasma. Decreased phagocytosis may decrease those parts of the septic 
inflammatory response being related to neutrophil activation and oxidative burst, i.e. release of 
reactive oxygen metabolites and other products thought to be important in some of the 
pathophysiological changes of sepsis, particularly capillary leakage.44 However, increased 
concentrations of circulating pathogens, even if they are dead due to adequate antibiotic 
treatment, may also increase the exposure of pathogen associated molecular patterns to their 
respective receptors including the Toll-like receptors and consequently increase the 
inflammatory response with increased secretion of pro-inflammatory cytokines.45 Also, 
inflammatory cells in organs more vulnerable to inflammation than the liver and spleen, like 
the lungs and the kidneys may be more activated. An alternative strategy is to inhibit 
complement at a later step such as blocking the potent anaphylatoxin C5a by blocking C5aR, 
which implies that the bacteria will still be fully opsonizied and may bind to both erythrocyte 
and leukocyte CR1. According to the results in this and previous studies,16 C5aR inhibition 
would substantially decrease granulocyte phagocytosis due to diminished up-regulation of 
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CR3. However, according to our results phagocytosis by monocytes and thus, possibly also 
tissue macrophages in the liver and spleen, would be better maintained with C5aR inhibition 
than with inhibition of previous steps with decreased complement opsonization. Accordingly, 
inhibition of C5aR may be an attractive approach when searching for a complement inhibitor 
to be used in sepsis since it did not affect the binding of bacteria to erythrocytes. 
In conclusion, the present data provide new and important insights into the initial interaction 
of Gram-negative bacteria with erythrocytes and leukocytes in human whole blood and give 
some indications on how bacterial binding to erythrocyte CR1 influence the handling of the 
bacteria in vivo. The mechanisms described are suggested to be of clinical importance in 
sepsis and especially in the development of complement inhibitors as potential therapeutic 
agents in sepsis. 
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Figure legends
Figure 1. Dose-response effect of E. coli on the early binding to erythrocytes, complement 
activation and phagocytosis in human whole blood. Alexa-labeled E. coli was added to 
fresh whole blood (72 x 106 bacteria/mL) and incubated 10 minutes at 37oC. (A) Free bacteria 
in plasma (filled circles) and erythrocyte bound bacteria (open triangles) were analyzed using 
flow cytometry and results are given as 106 bacteria/mL. (B) Phagocytosis in granulocytes 
(open triangles) and monocytes (open circles) was analyzed using flow cytometry and given as 
median fluorescence intensity (MFI). (C) Complement activation was analyzed as the terminal 
complement complex (TCC) in plasma using ELISA and expressed as arbitrary units AU/mL 
(filled triangles). Data are presented as means and SD from three to six independent 
experiments using different blood donors each time. (D, E, F) Microscopy of Alexa-labeled E. 
coli bacteria in whole blood smears made after 10 minutes incubation (1000x magnification). 
Combined reflected fluorescence and transmitted light microscopy was performed according 
to the microscope instructions using very weak transmitted light intensity. The Olympus 
BX51TRF microscope was equipped with a ColorView IIIu digital camera with 5 megapixel 
resolution and was controlled by the CellP program (Soft imaging system, Münster, 
Germany). (D) E. coli bound to erythrocytes, (E) E. coli phagocytosed in a leukocyte and (F) 
E. coli free in plasma. Results from one of five representative experiments are shown.
Figure 2. Effect of complement inhibitors on the binding of E. coli to erythrocytes and 
phagocytosis in granulocytes and monocytes. Alexa-labeled E. coli (72 x 106/mL) was 
added to human whole blood and incubated at 37oC for 10 minutes in the presence of mAbs 
blocking C2 and factor D (Anti-C2/D), an isotype control (Ctr. mAb), a C5aR antagonist 
(C5aRa) and its corresponding control peptide (Ctr. pep.), or EDTA. (A) E. coli in plasma and 
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(B) erythrocyte bound E. coli was analyzed using flow cytometry and expressed as 106
bacteria/mL (Bact. 106/mL). Bacteria added to PBS in the absence of whole blood were 
included as a control (hatched bar to the right). Granulocyte (C) and monocyte (D) 
phagocytosis of E. coli with (black bars) and without quenching solution (white bars) was 
analyzed using flow cytometry and given as median fluorescence intensity (MFI). Results are 
presented as means and SD of data from three to six different blood donors. *P <0.05
compared to E. coli alone using one-way repeated measurements ANOVA and the Holm-
Sidak post test.
Figure 3. Time course of E. coli binding to erythrocytes, phagocytosis and effect of 
complement inhibitors. Alexa-labeled E. coli (72 x 106/mL) was added to human whole 
blood and incubated for up to 120 minutes (37oC). (A) E. coli in plasma and (B) erythrocyte 
bound E. coli and (C) granulocyte phagocytosis with quenching solution were analyzed using 
flow cytometry. Complement inhibitors added: compstatin (black triangle), its control peptide 
(white triangle), C5aRa (white square) and PBS control (black circles). The calcium chelator
EDTA (black diamond) was included as a control. Results are presented as means and SD 
(n=3) using different blood donors. *P <0.05 compared to E. coli plus PBS as control group 
analyzed after 120 minutes incubation using one-way repeated measurements ANOVA
followed by the Holm-Sidak post-test. 
Figure 4. Effect of complement inhibitors on E. coli and N. meningitidis C3 and C4 
opsonization. The effect of complement inhibitors compstatin, its corresponding control 
peptide (Ctr. peptide) and a C5aRa on bacterial C3 and C4 opsonization was examined. (A,B) 
E. coli (72 x 106/mL ), (C,D) N. meningitidis (72 x 106/mL) with LPS (black bars) or the LPS 
deficient 44/76lpxA-mutant (white bars) were incubated 10 minutes in lepirudin plasma 
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(+Plasma) supplemented with PBS or complement inhibitors as indicated. The calcium 
chelator EDTA which efficiently inhibits complement was included as control. Bacterial C3 
(A,C) and C4 (B,D) opsonization was analyzed using flow cytometry and results given as 
median fluorescence intensity (MFI). Results are given as means and SD from separate 
experiments using plasma from three different healthy donors.*P <0.05 compared to bacteria 
in PBS alone by one-way repeated measurements ANOVA followed by the Holm-Sidak post-
test. 
Figure 5. Effect of the anti-CR1 blocking mAb 3D9 on free E. coli in plasma, E. coli on 
erythrocytes, phagocytosis and oxidative burst. The anti-CR1 blocking mAb 3D9 was 
added in increasing concentrations to whole blood without (open diamonds) or with 72 x 106
E. coli/mL (black circles) added. (A,B) Free E. coli in plasma (A) and bacteria bound to 
erythrocytes (B) was analyzed using flow cytometry and given as 106 bacteria/mL (Bact.
106/mL). (C) Phagocytosis with (filled symbols) and without quench (open symbols) was 
analyzed in granulocytes (open and filled triangles). Effect of the isotype matched control 
mAb G3-519 (open and filled squares) is indicated. Data from one representative of three 
experiments are shown. (D) Granulocyte oxidative burst in the absence of E. coli (open 
diamond) and after stimulation with E. coli in the presence of anti-CR1 (filled circles) or a 
control mAb (open squares) analyzed using flow cytometry and given as median fluorescence 
intensity (MFI). Data are given as means and SD (n=3). *P<0.05 compared to the E. coli +
PBS control. 
Figure 6. Effect of the anti-CR1 blocking mAb 3D9 on the binding to erythrocytes of E. 
coli, N. meningitidis with LPS and N. meningtitidis without LPS. Whole blood was 
incubated with 72 x 106 bacteria/mL in the presence of PBS, anti-CR1 mAb 3D9 (Anti-CR1, 4 
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g/mL), an isotype matched control mAb (Ctr. mAb, 4 g/mL) or the calcium chelator EDTA. 
In addition, bacteria added to PBS in the absence of whole blood were included as a control 
(hatched bar to the right). The number of free bacteria in plasma (white bars), and bacteria 
bound to erythrocytes (black bars) was analyzed using flow cytometry and given as 106
bacteria/mL (Bact.106/mL). Data are given as means and SD from individual experiments with 
three different blood donors. *P<0.05 analyzed by one-way repeated measurements ANOVA 
using the Holm-Sidak post-test and multiple comparisons versus the bacteria plus PBS as 
control group. 
Figure 7. The time course after intravenous infusion of bacteria in pigs analyzed using 
qPCR. (A) E. coli and (B) N. meningitidis genome were quantified in whole blood samples 
from two different experiments using qPCR and expressed as bacteria/mL (log scale). Results 
are given as means and SD. (C, D) The fraction of bacteria in erythrocyte (black bar), buffy 
coat (white bar) and plasma fractions (hatched bar) expressed as % of total bacteria 
concentration. 
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Figure S1. Microscopy of N. meningitidis binding to erythrocytes in human whole blood 
smears. Alexa-labeled N. meningitidis (72 x 106 bacteria/mL) were added to human whole 
blood. After 10 minutes incubation, blood smears were made and the samples analyzed using 
combined fluorescence and transmitted light microscopy (1000x magnification) on a Olympus 
BX51TRF microscope equipped with a ColorView IIIu digital camera. (A) N. meningitidis 
bound to erythrocytes, B: N. meningitidis free in plasma, (C) N. meningitidis phagocytosed in 
a leukocyte. Results from one of three representative experiments are shown.  
  
 
Figure S2. Effect of complement inhibitors on the binding of N. meningitidis 44/76 to 
erythrocytes. The effect of complement inhibitors on free N. meningitidis (N.m.) in plasma, 
bound to erythrocytes and granulocyte and monocyte phagocytosis in human whole blood. 
Alexa-labeled N. meningitidis (72 x 106/mL) were added to human whole blood and incubated 
at 37oC for 10 minutes in the presence or absence of PBS, anti-C2 and anti-factor D (Anti-
C2/D), its corresponding control mAb (Ctr. mAb) , compstatin, C5aRa, a control peptide (Ctr. 
pep.) or EDTA. (A) N. meningitidis in plasma and (B) erythrocyte bound N. meningitidis were 
analyzed using flow cytometry and expressed as 106 bacteria/mL (Bact. 106/mL). Granulocyte 
(C) and monocyte phagocytosis (D) of bacteria was analyzed using flow cytometry and 
expressed as MFI. Phagocytosis was analyzed with (black bars) and without (white bars) 
quenching solution, reflecting phagocytosed and phagocytosed plus surface bound bacteria, 
respectively. Results are given as means and SD of three different blood donors. *P<0.05 
compared to N. meningitidis alone using one-way repeated measurements ANOVA and the 
Holm-Sidak post-test. 
 
 
 
 
 
 Figure S3. Microscopy of E. coli in porcine lung, liver and spleen in vivo. Alexa-stained 
E. coli (green color) were infused intravenously in pigs. After 4 hours, the organs were frozen 
and immunofluorescence histology was performed on cryosections obtained from the (A) 
lung, (B) liver and (C) spleen. Cryosections (5 μm thick) were cut from tissue embedded and 
snap-frozen in O.C.T Compound (Tissue-Tek; BDH, Lutterworth, UK). Sections were air 
dried and fixed for 10 minutes in ice-cold acetone. Fc receptors were blocked by incubating 
the sections for 30 minutes with PBS containing 5% pig serum and 5% goat serum. To 
identify tissue macrophages, a pretitrated anti-porcine CD45 monoclonal antibody (a kind gift 
from Karin Haverson, University of Bristol, Bristol, UK) was applied and incubated for 2 
hours. Slides were washed thoroughly 3 times with PBS for 5 minutes. An isotype-specific 
goat anti-mouse antiserum (Southern Biotechnology, Birmingham, AL) conjugated to Texas 
Red was then applied and incubated for 1 hour. The slides were washed three more times, and 
the nuclear dye DAPI was applied and incubated for 10 minutes. After a final wash, the 
sections were mounted in Fluoromount (Vector Laboratories, Burlingame, CA) and sealed 
with nail varnish. Stained slides were examined using a Nikon Eclipse E800 microscope 
(Nikon, Tokyo, Japan) fitted with a combined excitation and emission filter block specific for 
the applied fluorescence staining. Samples were analyzed by fluorescence microscopy using 
200x magnification. Macrophages was stained using Texas Red (red color) and cellular nuclei 
were stained using DAPI (blue color). 
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